WORLD SYMPOSIUM ON PULMONARY HYPERTENSION

Nice
February 27-28 / March 1, 2018
INTRODUCTION

Traditionally the PH World Symposia series, started in Geneva in 1973 and held every 5 years after the Evian edition in 1998 (Venice 2003, Dana Point 2008, Nice 2013), has marked the progresses in pulmonary hypertension science and has anticipated future developments. The published supplement including the symposia proceedings constitutes a collection of articles among the most cited in this scientific area.

Each new edition of the WSPH series has increased the attendance compared with the previous one, testifying the growing interest of the stakeholders of this area. More than 1200 international physicians attended the 5th WSPH - Nice 2013.

The structure of the 6th WSPH consists in 13 sessions where world specialists in the field, divided in 13 Task Forces, present the results of their studies developed in the last two years and regarding some topic items:

1. Pathology & Pathobiology
2. Genetics & Genomics
3. Pathophysiology of the RV and of the Pulmonary Circulation
4. PH Haemodynamic Definitions and Clinical Classifications and Characteristics of Specific PAH Subgroups
5. Diagnosis of Pulmonary Hypertension
6. Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension
7. Right Ventricular Assistance and Lung Transplantation
8. Trials Design & New Therapies for Pulmonary Arterial Hypertension
9. PH due to Left Heart Diseases
10. PH due to Chronic Lung Diseases
11. CTEPH
12. Pediatric PH
13. Patients’ Perspectives

The objectives of the 6th WSPH are:
• Review of the major advances in pulmonary vascular science in the past 5 years
• Analyze the available evidence in different basic and clinical areas by expert task forces
• Evaluation of the gaps of evidence in different areas and proposals for future collaborative research programs
• Elaboration of documents by the task forces, summarizing the results of pre-symposium meetings (previous 18-24 months)
• Discussion of the task forces documents at the symposium sessions with worldwide experts and with other stakeholders
• Final drafting of peer reviewed papers to be included in a supplement (prestigious medical journal) to facilitate the implementation of the 6th WSPH conclusions.

Our purpose is to foster with the Symposium constructive scientific interactions and collaborations in the very unique scenario of the bay of Nice.

For the Steering Committee
Nazzareno Galiè
Vallerie V. McLaughlin
Lewis J. Rubin
Gérald Simonneau
ENDORSEMENTS

The Symposium Steering Committee

• Adaani Frost, MD
  Houston, TX - USA
• Nazzareno Galiè, MD
  Bologna, Italy
• Ardeschir H. Ghofrani, MD
  Giessen, Germany
• Marc Humbert, MD
  Paris, France
• Anne Margaret Keogh, MD
  Sydney, Australia
• Michael D. McGoon, MD
  Rochester, MN - USA
• Vallerie V. McLaughlin, MD
  Ann Arbor, MI - USA
• Nicholas W. Morrell, MD
  Cambridge, UK
• Lewis J. Rubin, MD
  San Diego, CA - USA
• Werner Seeger, MD
  Giessen, Germany
• Gérald Simonneau, MD
  Paris, France
• Rogerio Souza, MD
  Sao Paulo, Brazil

The Symposium Secretariat

I&C s.r.l.
Via Andrea Costa, 202/6
40134 Bologna (IT)
Stefania Parolari and Giulia Delia
Ph: +39 - 051.614.4004
Fax: +39 - 051.614.2772
@: info@wsph2018.com
www.wsph2018.com
## Index

- MAP OF THE CONGRESS CENTER .......................................................... 00
- SYMPOSIUM TIMETABLE ................................................................. 00
- SCIENTIFIC PROGRAM ................................................................. 00

### TUESDAY, FEBRUARY 27
- TASK FORCE 1 – Pathology & Pathobiology ........................................ 00
- TASK FORCE 2 – Genetics and Genomics ............................................ 00
- TASK FORCE 3 – Pathophysiology of the RV and of the Pulmonary Circulation ......................................................... 00
- TASK FORCE 4 – PH Haemodynamic Definitions and Clinical Classifications and Characteristics of Specific PAH Subgroups ........................................................................................................... 00
- TASK FORCE 5 – Diagnosis of Pulmonary Hypertension .................. 00

### WEDNESDAY, FEBRUARY 28
- TASK FORCE 6 – Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension ................................................................. 00
- TASK FORCE 7 – Right Ventricular Assistance and Lung Transplantation ........................................................................................................... 00
- TASK FORCE 8 – Trials Design & New Therapies for Pulmonary Arterial Hypertension ........................................................................... 00
- TASK FORCE 9 – PH due to Left Heart Diseases ................................. 00

### THURSDAY, MARCH 1
- TASK FORCE 10 – PH due to Chronic Lung Diseases ......................... 00
- TASK FORCE 11 – CTEPH .................................................................. 00
- TASK FORCE 12 – Pediatric PH ......................................................... 00
- TASK FORCE 13 – Patients’ Perspectives .............................................. 00

- POSTER SESSIONS ............................................................................ 00
- BEST POSTER AWARDS ..................................................................... 00
- POSTERS EXPOSED ON TUESDAY, FEBRUARY 27 ....................... 00
- POSTERS EXPOSED ON WEDNESDAY, FEBRUARY 28 ................. 00
- POSTERS EXPOSED ON THURSDAY, MARCH 1 .............................. 00

- GENERAL INFORMATION ................................................................. 00
- INDEX OF POSTERS AUTHORS AND TASK FORCES MEMBERS ........ 00
- SPONSORS ......................................................................................... 00
Map of the Acropolis

CONGRESS CENTER

Agora 1

Agora 2

Agora 3

REGISTRATION DESKS AND ASSOCIATION BOOTHS

SLIDE CENTER

CLOAKROOM

MAIN ENTRANCE

POSTERS AND COFFEE BREAK AREA

APOLLON MEETING HALL

MYKONOS BAR AND RELAX AREA

LUNCH AREA

LUNCH AREA
<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday, February 27</th>
<th>Wednesday, February 28</th>
<th>Thursday, March 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.00</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>TF 1. Pathology &amp; Pathobiology</td>
<td>TF 6. Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension</td>
<td>TF 10. PH due to Chronic Lung Diseases</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>coffee break</td>
<td>coffee break</td>
<td>coffee break</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>TF 2. Genetics &amp; Genomics</td>
<td>TF 7. Right Ventricular Assistance and Lung Transplantation</td>
<td>TF 11. CTEPH</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Best Poster Awards Ceremony</td>
<td>Lunch and posters</td>
<td>Lunch and posters</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch and posters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>coffee break</td>
<td>coffee break</td>
<td>coffee break</td>
</tr>
<tr>
<td>16.00-17.30</td>
<td>TF 4. PH Haemodynamic Definitions and Clinical Classifications and Characteristics of Specific PAH Subgroups</td>
<td>TF 9. PH due to Left Heart Diseases</td>
<td>TF 13. Patients' Perspectives</td>
</tr>
<tr>
<td>17.30-19.00</td>
<td>TF 5. Diagnosis of Pulmonary Hypertension</td>
<td></td>
<td>Final remarks and next steps</td>
</tr>
</tbody>
</table>

TF = Task Force
Scientific Program
TUESDAY, FEBRUARY 27

**Apollo Hall**

**08.30 - 09.00**

**Opening Ceremony**

Nazzareno Galiè, Bologna ITALY
Valerie V. McLaughlin, Ann Arbor MI USA
Lewis J. Rubin, La Jolla CA USA
Gérald Simonneau, Paris FRANCE

**09.00-10.30**

**Task Force 1. Pathology & Pathobiology**

CHAIR: MARC HUMBERT, Paris FRANCE
CHAIR: MARLENE RABINOVITCH, Stanford CA USA
SEBASTIEN BONNET, Chemin Sainte-Foy CANADA
PETER DORFMÜLLER, Paris FRANCE
CHRISTOPHE GUIGNABERT, Le Plessis Robinson FRANCE
JAMES R. KLINGER, Rhode Island RI USA
MARK R. NICOLLS, Stanford CA USA
ANDREA J. OLSCHEWSKI, Graz AUSTRIA
SONI SAVAI PULLAMSETTI, Bad Nauheim GERMANY
RALPH T. SCHERMULY, Giessen GERMANY
KURT R. STENMARK, Aurora CO USA

Objectives:
- State of the art
- Main bench to bedside achievements
- Recommendation on how to identify most relevant pathways
- Most appropriate cells, tissues and animal models
- Proposed Future Directions (specific and detailed)

**Agora 2**

**10.30-11.00**

coffee break

**Apollo Hall**

**11.00-12.30**

**Task Force 2. Genetics & Genomics**

CHAIR: NICHOLAS W. MORRELL, Cambridge UK
CHAIR: JAMES E. LOYD, Nashville TN USA
Micheala ALDRED, Cleveland OH USA
WENDY KAY CHUNG, New York NY USA
GREGORY ELLIOTT, Salt Lake City UT USA
WILLIAM NICHOLS, Cincinnati OH USA
FLORENT SOUBRIER, Paris FRANCE
RICHARD C. TREMBATH, London UK

Objectives:
- State of the art
- Pathobiology links between mutations and disease (why low penetrance)
- Genetic counselling and healthy mutation carriers
- Practical application of genomics
- Proposed Future Directions (specific and detailed)

**12.30-13.00**

Best Poster Awards Ceremony

**Agora 2 and 3**

**13.00-14.00**

Lunch and posters
Scientific Program

TUESDAY, FEBRUARY 27

**APOLLON HALL**
14.00-15.30

Task Force 3. Pathophysiology of the RV and of the pulmonary circulation

**CHAIR:** ROBERT NAEJE, Brussels BELGIUM  
**CHAIR:** ANTON VONK NOORDEGRAAF, Amsterdam THE NETHERLANDS  
KELLY MARIE CHIN, Dallas TX USA  
FRANÇOIS HADDAD, Palo Alto CA USA  
PAUL M. HASSOUN, Baltimore MD USA  
ANNA R. HEMNES, Nashville TN USA  
SUSAN R. HOPKINS, San Diego CA USA  
STEVEN M. KAWUT, Philadelphia PA USA  
DAVID LANGLEBEN, Montreal CANADA  
JOOST LUMENS, Maastricht THE NETHERLANDS

Objectives:
- State of the Art  
- Main bench to bedside achievements  
- MRI, echocardiography and metabolic studies  
- Early detection and irreversibility thresholds of RV dysfunction  
- Proposed Future Directions (specific and detailed)

**AGORA 2**
15.30-16.00

coffee break

16.00-17.30

Task Force 4. PH haemodynamic definitions and clinical classifications and characteristics of specific PAH subgroups

**CHAIR:** GERALD SIMONNEAU, Paris FRANCE  
**CHAIR:** ROGERIO SOUZA, Sao Paulo BRAZIL  
DAVID S. CELERMAJER, Sydney AUSTRALIA  
CHRISTOPHER P. DENTON, London UK  
MICHAEL A. GATZOLIS, London UK  
MICHAEL KROWKA, Rochester MN USA  
DAVID MONTANI, Paris FRANCE  
PAUL WILLIAMS, Johannesburg SOUTH AFRICA

Objectives:
- State of the art  
- Haemodynamic definitions  
- Atypical PAH  
- PVOD

17.30 – 19.00

Task Force 5. Diagnosis of pulmonary hypertension

**CHAIR:** ADAANI FROST, Houston TX USA  
**CHAIR:** ADAM TORBICKI, Otwock POLAND  
DAVID B. BADESCH, Aurora CO USA  
SIMON GIBBS, London UK  
DEEPA GOPALAN, London UK  
DINESH KHANNA, Ann Arbor MI USA  
ALESSANDRA MANES, Bologna ITALY  
RONALD J. OUDIZ, Torrance Los Angeles CA USA  
TORU SATOH, Mitaka JAPAN  
FERNANDO TORRES, Dallas TX USA

Objectives:
- State of the art  
- Practice recommendations  
- New diagnostic tools?  
- Proposed future directions (specific and detailed)
Scientific Program

WEDNESDAY, FEBRUARY 28

APOLLO HALL
09.00-10.30
Task Force 6. Risk stratification and medical therapy of pulmonary arterial hypertension
CHAIR: NAZZARENO GALIÈ, Bologna ITALY
CHAIR: VALLERIE V. MCLAUGHLIN, Ann Arbor MI USA
RICHARD N. CHANNICK, Boston MA USA
ROBERT P. FRANTZ, Rochester MN USA
EKKEHARD GRÜNIG, Heidelberg GERMANY
ZHI CHENG JING, Beijing CHINA
IOANA R. PRESTON, Boston MA USA
TOMAS PULIDO, Mexico City MEXICO
ZEENAT SAFDAR, Houston TX USA
YUICHI TAMURA, Tokyo JAPAN

Objectives:
- State of the art
- Practice recommendations
- General measures and non-specific therapy (pregnancy, a/c therapy, rehabilitation)
- Proposed future directions (specific and detailed)

AGORA 2
10.30-11.00
coffee break

APOLLO HALL
11.00-12.30
Task Force 7. Right ventricular assistance and lung transplantation
CHAIR: WALTER KLEPETKO, Vienna AUSTRIA
CHAIR: MARIUS HOEPER, Hanover GERMANY
RAYMOND L. BENZA, Pittsburgh PA USA
PAUL A. CORRIS, Newcastle Upon Tyne UK
MARC DE PERROT, Toronto CANADA
ELIE FADEL, Paris FRANCE
ANNE M. KEOGH, Sydney AUSTRALIA
CHRISTIAN KÜHN, Hanover GERMANY
LAURENT SAVALE, Paris FRANCE

Objectives:
- State of the art
- ICU management of severe PH
- Practice recommendations
- Proposed future directions (specific and detailed)

AGORA 2 and 3
12.30-14.00
Lunch and posters

APOLLO HALL
14.00-15.30
Task Force 8. Trials design and new therapies for pulmonary arterial hypertension
CHAIR: LEWIS J. RUBIN, La Jolla CA USA
CHAIR: OLIVIER SITBON, Paris FRANCE
CHRISTINE GARNETT, Silver Spring MD USA
AMANY N. EL-GAZAYERLY, The Hague THE NETHERLANDS
MARDI I. GOMBERG MAITLAND, Falls Church VA USA
JOHN GRANTON, Toronto CANADA
MICHAEL I. LEWIS, Los Angeles CA USA
STEPHEN C. MATHAI, Baltimore MD USA
MAURIZIO RAINISIO, Imperia ITALY
NORMAN STOCKBRIDGE, Silver Spring MD USA
MARTIN R. WILKINS, London UK
ROHAM ZAMANIAN, Stanford CA USA

Objectives:
- State of the art
- Current challenges
- Proposed future directions (specific and detailed)

AGORA 2
15.30-16.00
coffee break
Scientific Program

WEDNESDAY, FEBRUARY 28

APOLLON HALL
16.00-17.30

Task Force 9. PH due to left heart diseases
CHAIR: JEAN LUC VACHIERY, Brussels BELGIUM
CHAIR: TERESA DE MARCO, San Francisco CA USA
IRINA CHAZOVA, Moscow RUSSIAN FEDERATION
JOHN G. COGHLAN, London UK
MARCO GUZZI, Milan ITALY
IRENE LANG, Vienna AUSTRIA
MASSIMILIANO PALAZZINI, Bologna ITALY
STEPHAN H. ROSENKRANZ, Cologne GERMANY
RYAN J. TEDFORD, Baltimore MD USA

Objectives:
- State of the art
- Current challenges
- Vasoreactivity testing in left heart disease
- Proposed future directions (specific and detailed)

THURSDAY, MARCH 1

APOLLON HALL
09.00-10.30

Task Force 10. PH due to chronic lung diseases
CHAIR: WERNER SEEGER, Giessen GERMANY
CHAIR: STEVEN D. NATHAN, Falls Church VA USA
JOAN ALBERT BARBERÀ, Barcelona SPAIN
SEAN P. GAINÉ, Dublin IRELAND
SERGIO HARARI, Milan ITALY
FERNANDO JOSE MARTINEZ, Ann Arbor MI USA
HORST OLSCHIEWSKI, Graz AUSTRIA
KAREN M. OLSSON, Hanover GERMANY
ANDREW J. PEACOCK, Glasgow UK
JOANNA PEPKE-ZABA, Cambridge UK
STEEVE PROVENCHER, Chemin Sainte-Foy CANADA
NORBERT WEISSMANN, Giessen GERMANY

Objectives:
- State of the art
- Current challenges
- Proposed future directions (specific and detailed)

AGORA 2
10.30-11.00
coffee break
Scientific Program

THURSDAY, MARCH 1

APOLLON HALL
11.00-12.30
Task Force 11. CTEPH
CHAIR: ARDESHIR H. GHOFRANI, Giessen GERMANY
CHAIR: NICK H. KIM, La Jolla CA USA
CHAIR: DAVID P. JENKINS, Cambridge UK
MARION DELCROIX, Leuven BELGIUM
XAVIER JAIS, Paris FRANCE
MICHAEL M. MADANI, San Diego CA USA
HIROMI MATSUBARA, Osaka JAPAN
ECKHARD MAYER, Bad Nauheim GERMANY
TAKEHI OGO, Paris FRANCE
MICHAEL M. MADANI, San Diego CA USA
Objectives:
- State of the art
- Current challenges
- Treatment selection
- Proposed future directions (specific and detailed)

AGORA 2 and 3
12.30-14.00
Lunch and posters

APOLLON HALL
14.00-15.30
Task Force 12. Pediatric PH
CHAIR: ERIKA BERMAN ROSENZWEIG, New York NY USA
CHAIR: ROLF M.F. BERGER, Groningen THE NETHERLANDS
STEVEN ABMAN, Aurora CO USA
IAN T. K. ADATIA, Edmonton CANADA
MAURICE BEGHETTI, Geneve SWITZERLAND
DAMIEN BONNET, Paris FRANCE
SHEILA G. HAWORTH BASK, London UK
DAVID D. IVY, Aurora CO USA
Objectives:
- State of the art
- Current challenges
- Proposed future directions (specific and detailed)

AGORA 2
15.30-16.00
coffee break

APOLLON HALL
16.00-17.30
Task Force 13. Patients’ perspectives
CHAIR: MICHAEL D. MCGOON, Rochester MN USA
CHAIR: PISANA FERRARI, Milan ITALY
IAIN ARMSTRONG, Sheffield UK
MIGDALIA DENIS, Miami FL USA
LUKE S. HOWARD, London UK
SANJAY MEHTA, London CANADA
NORIKO MURAKAMI, Yamatoshi JAPAN
BRAD A. WONG, Silver Spring MD USA
Objectives:
- Mission
- Narrative medicine (disease, illness, sickness)
- Current challenges
- Proposed future directions (specific and detailed)

17.30-18.00
Final remarks and next steps
Nazzareno Galiè, Vallerie V. McLaughlin, Gérald Simonneau, Lewis J. Rubin
POSTER SESSION

BEST POSTER AWARDS

These posters will be exposed for the whole period of the World Symposium: February 27, 28 and March 1

BASIC SCIENCE

1  IMMUNE REPERTOIRE-BASED SIGNATURES IN THE BLOOD AND IN THE LUNG VESSEL-ASSOCIATED TERTIARY LYMPHOID TISSUE IN PRE-CAPILLARY PULMONARY HYPERTENSION

Sylvia Cohen-Kaminsky[4], Sébastien J Dumas[2], Isabelle Klingel-Schmitt[1], Matthieu Vocelle[2], Anais Courtier[4], Orchidee Filipe-Santo[4], Gilles Parmentier[4], Solène Perez[4], Caroline Suberbielle[4], Sophie Caillat-Zucman[4], Gerald Simonneau[2], Frederic Perros[3], Marc Humbert[2], Morad Nahtleh[2], David Montani[2], Barbara Giererd[2], Andrei Seferian[2], Peter Dorfmüller[1]


2  A GENOME-WIDE ASSOCIATION STUDY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.

Michael Newnham*[1], Mark Toshner*[1], Marta Bleda*[1], William Auger[2], Joan Albert Barberà[3], Harv Jan Boggaard[4], John Cannor[5], Gerry Coghlan[6], Paul Corris[7], Marion Delcroix[8], John Dunning[9], Heath Elding[9], Simon Gibbs[9], Charaka Hadinnapola[9], David Jenkins[9], David Kiely[11], Irene Lang[12], Eckhard Mayer[13], Choo Ng[14], Andrew Peacock[15], Nicholas Screaton[16], Karen Sheares[17], Michael Simpson[17], Nicole Soranzo[17], Dolores Taboada[17], Richard Trembath[17], Steven Tsui[17], Martin Wilkins[17], Stephen John Wort[17], Joanna Pepke-Zaba[17], Nicholas Morrell[17]


3  GENETIC ANALYSIS OF 2,156 WHO GROUP 1 PAH PATIENTS ENROLLED IN THE PAH BIOBANK

Michael Pauciulo*, Katie Lutz, Anna Walsworth, Lisa Martin, William Nichols

Cincinnati Children’s Hospital Medical Center – Cincinnati ~ United States of America
BEST POSTER AWARDS
These posters will be exposed for the whole period of the World Symposium: February 27, 28 and March 1

CLINICAL SCIENCE

4 REDUCED RIGHT VENTRICULAR CONTRACTILE RESERVE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND BORDERLINE PULMONARY ARTERIAL PRESSURES
Centre for Pulmonary Hypertension at Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany ~ Heidelberg ~ Germany, Department of Rheumatology, University Hospital Heidelberg, Heidelberg, Germany ~ Heidelberg ~ Germany, Praxis für Rheumakardiologie und klinische Immunologie ~ Baden-Baden ~ Germany, Department of Human Genetics; University of Heidelberg; ~ Heidelberg ~ Germany, Department of Radiology, Cardiology Division, “Cava de’ Tirreni and Amalfi Coast” Hospital, University of Salerno, Salerno, Italy ~ Salerno ~ Israel

5 RISK ASSESSMENT IN SCLERODERMA PATIENTS WITH NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION: APPLICATION OF THE ESC/ERS RISK PREDICTION MODEL
Valentina Mercurio*, Nermin Diab, Grace Peloquin, Rachel Damico, Todd Kolb, Stephen Mathai, Paul Hassoun
Johns Hopkins University ~ Baltimore ~ United States of America

6 IDENTIFICATION OF GENETIC DEFECTS IN PULMONARY ARTERIAL HYPERTENSION BY A NEW GENE PANEL DIAGNOSTIC TOOL
Thoraciclinic at the University Hospital Heidelberg ~ Heidelberg ~ Germany, European Molecular Biology Laboratory ~ Heidelberg ~ Germany, Institute of Human Genetics, Heidelberg University ~ Heidelberg ~ Germany

7 EFFECTIVENESS OF PERCUTANEOUS TRANSLUMINAL PULMONARY ANGIOPLASTY FOR LONG-TERM OUTCOMES IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Keio University School of Medicine ~ Tokyo ~ Japan, Kyorin University School of Medicine ~ Tokyo ~ Japan

8 SEQUENTIAL HYBRID THERAPY WITH PULMONARY ENDARTERECTOMY AND ADDITIONAL BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine ~ Kobe ~ Japan, Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine ~ Kobe ~ Japan

9 EARLY DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN APPARENTLY HEALTHY CHILDREN BY MANDATORY ELECTROCARDIOGRAPHY SCREENING: A JAPANESE NATIONWIDE SURVEY
Waseda University Graduate School of Medicine ~ Tokyo ~ Japan, Tohoku University Omori Medical Center ~ Tokyo ~ Japan, Keio University School of Medicine ~ Tokyo ~ Japan, Osaka University School of Medicine ~ Osaka ~ Japan, National Cerebral and Cardiovascular Center ~ Osaka ~ Japan, Toyama University School of Medicine ~ Toyama ~ Japan, Shizuoka Children’s Hospital ~ Shizuoka ~ Japan, Tokyo Women’s Medical University ~ Tokyo ~ Japan, Tokyo Medical and Dental University ~ Tokyo ~ Japan, Fukuoka Children’s Hospital ~ Fukuoka ~ Japan, Social Insurance Chukyo Hospital ~ Nagoya ~ Japan
Tuesday, February 27, 2018

PATHOLOGY AND PATHOBIOLOGY

A10 PAH-MIMICKING CHIP TO ELUCIDATE THE DISEASE PATHOGENESIS AND SCREEN ANTI-PAH DRUGS
Fakhrul Ahsan*, Taslim A Al Hilal, Ali Keshavarz
Texas Tech University Health Sciences Center – Amarillo – United States of America

A11 URIC ACID CAUSES EXCESSIVE PULMONARY ARTERIAL SMOOTH MUSCLE CELL PROLIFERATION VIA UREATV1 UPREGULATION IN PULMONARY ARTERIAL HYPERTENSION
Satoshi Akagi*, Tamura Yuichi, Tu Ly, Phan Carole, Thuillet Raphaël, Sékine Ayumi, Huertas Alice, Humbert Marc, Guignabert Christophe
INSERM UMR_S 999 / University of Paris-Sud / Université Paris-Saclay – Le Kremlin-Bicêtre – France

A12 HEPARAN SULFATE IMBALANCE AND FINE STRUCTURAL MODIFICATIONS OF THEIR SULFATION PATTERNS IN LUNG ARE ASSOCIATED WITH FUNCTIONAL EFFECTS IN PRECAPILLARY PULMONARY HYPERTENSION
Patricia Albanese[2], Sébastien Dumas[2], Benoit Ranchoux[2], Sara Shamdani[2], Sandrine Chantepey[2], Emilie Henault[2], David Montani[1], Barbara Girerd[3], Peter Dormuller[3], Elie Fadel[3], Philippe Dartevelle[3], Frederic Perros[3], Marc Humbert[1], Dulce Papy-Garcia[3], Sylvia Cohen-Kaminsky[3]

A13 EXPERIMENTAL AND HUMAN PULMONARY VENO-OCCCLUSIVE DISEASE: SIMILARITIES AND DIFFERENCES
Fabrice Antigny[4], Esther Noscent[3], Melanie Lambert[3], Benoit Ranchoux[1], Audrey Courboulin[1], Barbara Girerd[1], Florent Soubrier[1], Florence Lecerf[1], Aurélie Hautefort[1], Harm Jan Bogaard[1], Sébastien Dumas[3], Benoit Ranchoux[1], Marc Humbert[1], David Montani[1], Peter Dormuller[1], Frederic Perros[1]

A14 FORMINS MAY REGULATE ENDOTHELIAL TO MESCHYMAL TRANSITION VIA VASCULAR ENDOTHELIAL CELL DERIVED MESENCHYMAL STEM CELLS IN PAH
Meghan Bernier*, Anil Bhatta, Lewis Romner
Johns Hopkins School of Medicine – Baltimore – United States of America

A15 NEUTRALIZATION OF CXCL12 REVERSES PULMONARY VASCULAR REMODELING BY DECREASING PULMONARY ARTERIAL SMOOTH MUSCLE CELL ACCUMULATION
Jennifer Bordenave[1], Raphaël Thuillet[1], Ly Tu[1], Carole Phan[1], Gérald Simonneau[1], Alice Huertas[1], Marcel Hibert[1], Dominique Bonnet[1], Marc Humbert[1], Nelly Frossard[1], Christophe Guignabert[1]

A16 COMPREHENSIVE CHARACTERIZATION OF MESENCHYMAL STEM CELLS IN PAH
Kyunghee Byun[4], Hanul Choi[4], Seyeon Oh[4], Duk-Kyuong Kim[2], Byeong-Ju Lee[2], Jeongwon Ryu[4], Hae Ok Jung[4], Kevin Chung[4], Hanul Choi[4]
[1]Department of Cardiology, Sejong General Hospital – Bucheon – Korea, Republic of, [2]Department of Cardiovascular Medicine, Gachon University Gil Medical Center – Incheon – Korea, Republic of, [3]Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea – Seoul – Korea, Republic of, [4]Department of Cardiovascular Medicine, Gachon Cardiovascular Research Institute – Incheon – Korea, Republic of

A17 INDOLEAMINE-2,3-DIOXYGENASE AS A POTENTIAL THERAPEUTIC TARGET OF PULMONARY HYPERTENSION
Zongye Cai*, Richard Wb Van Duin, Dirk Jan Duncker, Daphne Merkus
Erasmus MC – Rotterdam – Netherlands

A18 APELIN-13 CO-TREATMENT WITH UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS IMPROVES ENGRAFTED CELL SURVIVAL AND INHIBITS MACROFAGE ACTIVATION IN PULMONARY ARTERIAL HYPERTENSION MURINE MODEL
Seungbum Choi[1], Byeong-Ju Lee[2], Seyeon Oh[3], Kuk Hui Son[2], Duk-Kyuong Kim[2], Hanul Choi[2], Jeongwon Ryu[2], Hae Ok Jung[4], Kyunghee Byun[4], Kevin Chung[4]
[1]Department of Cardiovascular Medicine, Gachon Cardiovascular Research Institute – Incheon – Korea, Republic of, [2]Department of Cardiovascular Medicine, Gachon University Gil Medical Center – Incheon – Korea, Republic of, [3]Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea – Seoul – Korea, Republic of, [4]Division of Cardiology, Department of Internal Medicine, Gachon Cardiovascular Research Institute – Incheon – Korea, Republic of

POSTER SESSION
A19 NMDA-TYPE GLUTAMATE RECEPTOR ACTIVATION PROMOTES VASCULAR REMODELING AND PULMONARY ARTERIAL HYPERTENSION
Sylvia Cohen-Kaminsky1, Sébastien J Dumais2, Gilles Bru-Mercier3, Audrey Courboulin4, Marceau Quatreduennes5, Catherine Rucker-Martin6, Fabrice Antigny2, Morad K Nakhele2, Benoit Ranchoux2, Elodie Gouadon2, Maria Candida Vinhas2, Matthieu Vocelle2, Nicolas Raymond2, Peter Dormüller2, Elie Fadel2, Frédéric Perros2, Marc Humbert6.
1INSERM UMR S 999, Hôpital Marie Lannelongue, Univ. Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Plessis-Robinson F-92350, AP-HP Assistance Publique-Hôp de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre F-94270, France –, 2INSERM UMR S 999, Hôpital Marie Lannelongue, Univ. Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Plessis-Robinson, F-92350 – France

A20 RASSF1A REGULATES HIF-1: TRIGGERING A FEED FORWARD LOOP IN HYPOXIA DRIVEN PULMONARY HYPERTENSION
Swati Dabral1, Christian Muecker1, Rajkumar Sava1, Chanil Valsarajan1, Astrid Wietelmann1, Gregg Svenzenas2, Christos Samakidis2, Norbert Weissmann2, Friedrich Grimmingen2, Werner Seegert2, Renhard Dammann2, Soni Sava2, Pullamsetti2.
1Max-Planck Institute for heart and lung research – Bad Nauheim – Germany, 2University of Giessen – Giessen – Germany, 3Johns Hopkins University School of Medicine – Baltimore – United States of America

A21 INFLUENCE OF 16ALPHA-OHE2 ON MIGRATION AND ARY HYDROCARBON RECEPTOR SIGNALLING IN BLOOD OUTFLOWTHelial CELLS IN PAH.
Nina Denver1, Craig Docherty1, Katie Yates Harvey1, Ruth Andrew1, Natalie Homer1, Nicholas Morrell1, Margaret Maclean1.
1University of Glasgow – Glasgow – United Kingdom, 2University of Edinburgh – Edinburgh – United Kingdom, 3University of Cambridge – Cambridge – United Kingdom

A22 A MEASUREMENT OF THE COMMON CAROTID ARTERY IN PATIENTS WITH PULMONARY HYPERTENSION
Gunnar Einarsson1, Dan Henroth1, Frida Ulander2, Tord Naessén1, Marita Larsson1, Gerhard Wikström2.
1Department of Women’s and Children’s Health, Obstetrics and Gynaecology, Uppsala University Hospital, Uppsala – Uppsala – Sweden, 2Department of Medical Sciences, Uppsala University Hospital, Uppsala – Uppsala – Sweden

A23 HISTONE DEACETYLASE 7 MEDIATES HYPOXIA-INDUCED MITOCHONDRIAL REPROGRAMING IN PULMONARY HYPERTENSION AND CANCER
Elisabetta Gamert1, Prakash Chelladurai2, Werner Seeger2, Soni Sava Pullamsetti2.
1(1) Max-Planck Institute for Heart and Lung Research – Bad Nauheim – Germany, 2Universities of Giessen and Marburg Lung Center (UGMLC) – Giessen – Germany

A24 COMPLEMENTARY AND INTEGRATED VALUE OF SIX-MINUTE WALK TEST, VE/VCO2 SLOPE AND RIGHT ATRIAL STRAIN IN EARLY DETECTION OF FUNCTIONAL IMPAIRMENT AND VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENTS
Miriam Gravellone1, Alia Giubertoni, Jacopo Zanaboni, Cristina Piccinino, Paolo Nicola Marino.
Clinical Cardiology, “Maggiore della Carità” Hospital – Novara – Italy

A25 BIOMARKER DISCOVERY IN PULMONARY ARTERIAL HYPERTENSION: EXERCISE TRAINING, OR NIGHTLY OXYGEN
Gabriele Grunig1, Christina Eichstaedt1, Nedim Durmus2, Stéphanie Saxer1, Konrad E Bloch1, Silvia Ulrich3, Ekkehard Gruenig2, Serhiy Pylawka2.
1NYU School of Medicine – New York – United States of America, 2Mira Analytics LLC – New York – United States of America

A26 CHARACTERIZATION OF RATS MUTATED IN BMPR2: THE MAIN GENETIC RISK FACTOR FOR PAH
Aurélie Hautefort1, Catherine Rucker-Martin1, Boris Manoury2, Melanie Lambert2, Angele Boet1, Florence Lecerf1, Peter Dormüller2, Séverine Ménoret3, Laurent Tesson3, Ignacio Anegor2, David Montani3, Barbara Gierer2, Marc Humbert5, Fabrice Antigny4, Frederic Perros2.
1INSERM UMR S 999, Hôpital Marie Lannelongue, Univ. Paris-Sud, Faculté de Médecine, Université Paris-Saclay – Le Plessis Robinson – France, 2INSERM UMR S 1180, Faculté de Pharmacie, Université Paris Sud – Château-Malabry – France, 3INSERM UMR 1064-ITUN; CHU de Nantes – Nantes – France, 4INSERM UMR S 999; Hôpital Marie Lannelongue, Univ. Paris-Sud, Faculté de Médecine, Université Paris-Saclay; AP-HP Assistance Publique-Hôp de Paris, Service de Pneumologie, Hôpital Bicêtre – Le Kremlin-Bicêtre – France
Tuesday, February 27, 2018

PATHOLOGY AND PATHOBIOLOGY

A27 PROPOSAL OF CLINICAL DIAGNOSTIC CRITERIA FOR PULMONARY VENO-OCLUSION DISEASE (PVOD) BASED ON THE PVOD REGISTRY STUDY IN JAPAN
Hatuei Ishibashi-Ueda*, Keiko Ohta-Ogo†, Seiichiro Sakao‡, Nobuhiro Tanabe∥, Tenuaki Oka∥, Masanori Kitaichi∥, Norifumi Nakaniishi∥, Toru Satoh∥, Hiromi Matsubara∥, Koichiro Tatsumi∥
†Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka – Japan.
‡Department of Respiratory Medicine, Graduate School of Medicine, Chiba University – Chiba – Japan.
∥Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University – Chiba – Japan.
∥Department of Pathology, Kindai University, Osaka – Japan.
∥Department of Cardiovascular Medicine, Minami-Osaka Hospital – Osaka – Japan.
∥Department of Pathology, National Hospital Organization Minami Wakayama Medical Center – Wakayama – Japan.
∥Department of Cardioiology, Kyojin University School of Medicine – Mitaka, Tokyo – Japan.
∥Department of Clinical Science, National Hospital Organization Okayama Medical Center – Okayama – Japan.

A28 SELENOPROTEIN P PROMOTES THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION – A POSSIBLE NOVEL THERAPEUTIC TARGET—
Nobuhiro Kikuchi*, Kimito Satoh†, Ryosuke Sawa†, Nobuhiro Yoits†, Mohammad Ali-Al-Abdullai†, Mohammad Abdal Hai Siddique†, Junichi Omura†, Tajiyo Satoh†, Masamichi Nogi†, Shinichiro Sunamura†, Satoshi Miyata†, Yoshiro Saito†, Yasushi Hoshikawa†, Yosshinori Okada†, Hiroaki Shimokawa†
†Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine – Sendai – Japan.
†Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University – Kyoto – Japan.
†Department of Thoracic Surgery, Fujita Health University School of Medicine – Aichi – Japan.
†Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University – Sendai – Japan

A29 ALTERED BMP SIGNALING BY ENDOTHELIN-1 TO ACCELERATE PROLIFERATION OF SMOOTH MUSCLE CELLS
Hidekazu Maruyama*, Satoshi Sakai†, Kazutaka Aonuma†
†University of Tsukuba – Tsukuba – Japan.
‡Moriyama Daichi General Hospital – Moriyama – Japan

A30 SMOOTH MUSCLE PRIMES ENDOTHELUM FOR REGENERATION BY LINKING METABOLISM TO EPIGENETICS
Kazuya Miyagawa*, Minyi Shi, Pin-Ch Chen, Jan Hennigs, Zhixin Zhao, Mouer Wang, Caiyun Li, Toshie Saito, Shalina Taylor, Silin Sa, Aiqin Cao, Lingli Wang, Michael Snyder, Marlene Rabinovitch
Stanford University School of Medicine – Stanford – United States of America

A31 COMPARATIVE PHYSIOLOGICAL EVALUATION OF THE STATUS OF PULMONARY HEALTH IN YOUNG SMOKERS AND NON-SMOKERS
Natalia Mokina*, Vasily Pyatin, Egor Mokin
Samara State Medical University – Samara – Russian Federation

A32 SCREENING OF AUTOANTIBODIES IN PATIENT WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND ITS VALIDATION IN PATIENT WITH PULMONARY HYPERTENSION
Akira Naito*, Tanabe Nobuhiro†, Hiwasa Takaki‡, Jujo Takayuki#, Sugiiro Toshihiko‡, Sakao Seichiro‡, Tatsumi Koichiro‡
‡Department of Respiratory Medicine, Graduate School of Medicine, Chiba University – Chiba – Japan.
‡Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University – Chiba – Japan.
‡Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University – Chiba – Japan.

A33 PULMONARY VASCULAR REMODELING PATTERNS AND EXPRESSION OF GCN2 IN PULMONARY VENO-OCCULUSIVE DISEASE.
Esther Nosent*, Antigny Fabrice†, David Montani‡, Harm Jan Bogaard†, Maria-Rosa Ghigna‡, Melanie Lambert‡, Vincent Thomas De Montpréville‡, Barbara Gireid‡, Xavier Jalil‡, Laurent Savale‡, Olaf Mercier†, Elie Fadel‡, Florent Soulier‡, Olivier Sitbon‡, Gérard Simonneau‡, Antoine Vonk, Noordegraaf‡, Marc Humbert‡, Frédéric Ferro‡, Peter Dormìüler‡
‡Department of Pulmonary Diseases, WU University Medical Center, Institute for Cardiovascular Research – Amsterdam – Netherlands.
‡INSERM UMR 5999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue – Paris – France.
‡National Reference Center of Pulmonary Hypertension, Department of Pulmonaryology and Intensive Care Unit for Respiratory Diseases, Hôpital Bicêtre, AP-HP Kremlin-Bicêtre – Paris – France.
‡Department of Pathology, Hôpital Marie Lannelongue – Paris – France.
‡Department of Thoracic and Vascular Surgery, Hôpital Marie Lannelongue – Paris – France.
‡Department of Clinical Genetics, hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris and UMR 5116-ICAN, INSERM, UPMC Sorbonne Universités – Paris – France

A34 WIDE COMPARATIVE STUDY ON ANTIPIROLIFERATIVE VS. VASODILATOR EFFECTS OF DRUGS USED FOR PULMONARY HYPERTENSION IN RAT AND HUMAN ARTERIES
Francisco Perez-Vizcaino*, Daniel Morales-Canó†, Bianca Barreira†, Laura Moreno†, Joan A Barbera†, Angel Cogolludo†
†University Complutense – Madrid – Spain.
‡Ciberés – Madrid – Spain
A35 GUT-LUNG CONNECTION IN PULMONARY ARTERIAL HYPERTENSION

Frederic Perros[1], Benoît Ranchoux[1], Amélie Bigorgne[2], Aurélie Hautefort[3], Barbara Girerd[1], Olivier Sitbon[2], David Montani[3], Marc Humbert[2], Colas Tcherakian[4]


A36 DASATINIB INCREASES ENDOTHELIAL PERMEABILITY LEADING TO PLEURAL EFFUSION

Carole Phan[1][5], Etienne-Marie Jutant[1], Ly Tu[1][5], Raphael Thulliet[1], André Seferiani[1], David Montani[2][5], Alice Huertas[1][5], Jan Van Bezu[2][5], Fabian Breijer[2][5], Anton Vonk Noordegraaf[2][5], Marc Humbert[1][5], Jurjan Armani[3][5], Christophe Guignabert[5]


A37 SHOULD WE CONSIDER PIRFENIDONE IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION?

Paul-Benoit Poble*, Ghigna Maria Rosa, Phan Carole, Tu Ly, Bordenable Jennifer, Cumont Amélie, Thulliet Raphaël, Huertas Alice, Humbert Marc, Dorfmüller Peter, Guignabert Christophe

INSERM UMR S 999 / Université Paris-Sud / Université Paris-Saclay – Le Kremlin-Bicêtre – France

A38 LUNG CANCER-ASSOCIATED PULMONARY HYPERTENSION: ROLE OF MICROENVIRONMENTAL INFLAMMATION BASED ON TUMOR CELL-IMMUNE CELL CROSSTALK

Soni Pullamsetti[1][4], Rajkumar Savai[3][4], Baktybek Kojonazarov[3][4], Samantha Storm[3][4], Henning Gall[3][4], Ylia Salazar[3][4], Janine Wolf[3][4], Andreas Weidert[3][4], Nefertiti El-Nikhely[3][4], Ardeschir Ghofram[2][4], Gabriele Kronbach[3][4], Ludger Fink[3][4], Stefan Gattenlöher[3][4], Ulf Rapp[3][4], Ralph Schermuly[3][4], Friedrich Grimminger[3][4], Werner Seege[3][4]


A39 MITOMYCIN C INDUCES PULMONARY HYPERTENSION AND PATHOLOGIC SIGNS OF PULMONARY VASCULAR OCCLUSIVE DISEASE IN RABBITS

Rozen Quarc[1][2], Allard Wagenena[2][5], Birger Tielemans[2][5], Aurélie Hautefort[3][5], Catharina Belge[1][2][5], Fabrice Antigny[3][5], David Montani[3][5], Marion Delcroix[1][5], Frédéric Perros[3][5]


A40 TRICHLOROETHYLENE-INDUCED PERMEABILITY OF THE PULMONARY VASCULAR ENDOTHELION: A ROLE IN THE DEVELOPMENT OF PULMONARY VENO-OCCCLUSIVE DISEASE?

Marianne Rou[1][2], Morad Nakhl[2][5], Florence Lecerf[2][5], Marc Humbert[1][5], David Montani[1][5], Frédéric Perros[3][5]


A41 BLOCKADE OF ENDOTHELIN RECEPTOR TYPE B PROMOTE APOPTOSIS IN HUMAN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS

Satoshi Sakai*, Hidekazu Maruyama, Taizo Kimura, Junya Honda, Kazuya Otsu, Satoshi Homma, Takashi Miyazaki, Kazutaka Aonuma

University of Tsukuba – Tsukuba – Japan.
Tuesday, February 27, 2018

PATHOLOGY AND PATHOBIOLOGY

A42 SHEAR-MEDIATED ERYTHROCYTE NITRIC OXIDE PRODUCTION IS DIFFERENTIALLY REGULATED IN PATIENTS WITH SICKLE CELL DISEASE
Jacqueline Szmuszko-vicz*, Silvie Suriary, Derek Ponce, Jon Detterich
Children’s Hospital Los Angeles – Los Angeles – United States of America

A43 THE SIX-TRANSMEMBRANE PROTEIN STAMP2 PROTECTS FROM PULMONARY ARTERIAL HYPTERTENSION VIA ACTIONS IN MONONUCLEAR CELLS
Henrik Ten Freyhaus*, Mahreen Batouli, Eva Berghausen, Marius Vantler, Stephan Rosenkrantz
Klinik III for Internal Medicin, Heart Center of the University of Cologne – Cologne – Germany

A44 PHENOTYPING OF PULMONARY ARTERIAL ENDOTHELIAL CELLS ISOLATED FROM PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPTERTENSION AT DIAGNOSIS
Birger Tielemans*[1], Allard Wagenaar[2], Mathias Leys[2], Catharina Belge[2], Marion Delcroix[2], Rozenn Quarc[2]

A45 BMPRII DRIVEN RESPONSE OF ENDOTHELIAL INTEGRITY AND ANGIogenesis IN HUMAN LUNG MICROVASCULAR ENDOTHELIAL CELLS
Birger Tielemans*[1], Rik Gijsbers[1], Annelies Michiels[1], Allard Wagenaa[2], Richard Farré Martí[2], Catharina Belge[2], Marion Delcroix[2], Rozenn Quarc[2]

A46 CONTRIBUTION OF BMP9 TO PULMONARY ARTERIAL HYPTERTENSION: ROLE OF ENDOTHELIN-1

A47 LONG NONCODING RNA TYKRIL PLAYS A ROLE IN PULMONARY HYPERTENSION BY CONTROLLING THE P53 MEDIATED REGULATION OF PDGFRß
Chanil Valasarajan[1], Christoph Zehnder[2], Serge Tha[3], Astrid Werner[3], Jöri-Niels Boeckel[3], Florian Bischoff[3], David John[2], Tyler Weinrick[2], Simone Glaser[2], Oliver Rossbach[2], Nicolas Jaé[2], Shemsi Demoll[2], Regina Hummel[2], Karl-Friedrich Kreitner[2], Christian Möllmann[2], Katharina Michalik[2], Wei Chen[2], Werner Seeeger[2], Shizuka Uchida[2], Andreas Zeiher[2], Stefanie Dimmeler[2], Soni Pullamsetti[2]
[1]Max Planck Institute for Heart and Lung Research, Department of Lung Development and Remodeling, member of 13 the German Center for Lung Research (DZL) – Bad Nauheim – Germany, [2]Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University Frankfurt am Main – Frankfurt am Main – Germany, [3]Department of Anesthesiology, University Medical Center Mainz – Mainz – Germany, [3]Institute of Biochemistry, University of Giessen – Giessen – Germany, [3]Department of Radiology, University Medical Center Mainz – Mainz – Germany, [3]Department of Biology, Southern University of Science and Technology – Guangdong – China, [2]M III, Department of Cardiology, Goethe University – Frankfurt am Main – Germany

A48 SEX HORMONE PROFILES PREDICT THE RISK AND SEVERITY OF DISEASE IN POST-MENOPAUSAL WOMEN WITH PULMONARY ARTERIAL HYPTERTENSION
Corey Ventetuolo*[1], Grayson Baird[2], R Graham Ban[3], David Bluemke[2], Andrew Foderaro[4], Jason Fritz[5], Nicholas Hill[5], James Klinger[1], Joao Lima[1], Pamela Ouyang[6], Harold Palevsky[4], Amy Palmisciano[4], Diane Pinder[6], Ioana Preston[5], Thomas Walsh[7], Kari Roberts[2], Steven Kawut[2]

A49 PLATELET FUNCTION ABNORMALITIES IN PULMONARY HYPTERTENSION
Eleni Vrigkou*, Iraklis Tsangaris, Argyrios Tsantes, Dimitrios Konstantinou, Athanasios Pappas, Frantzeska Frantzeskaki, Michalis Rizos, Stylianos Orfanos, Apostolos Armanagidis
Attikon University Hospital – Athens – Greece

A50 RECEPTOR TYROSINE KINASE SIGNALING DRIVING “PSEUDO-MALIGNANT” LUNG VASCULAR REMODELING - THERAPEUTIC EXPLOITATION
Naga Dinesh Reddy Yerabolu*
Justus Liebig university Giessen – Giessen – Germany
Tuesday, February 27, 2018

GENETICS AND GENOMICS

A51 THE UNITED STATES PULMONARY HYPERTENSION SCIENTIFIC REGISTRY (USPHSR): DESIGN AND INITIAL BASELINE CHARACTERISTICS
David Badesch[1], Adaani Frost[1], Eric Austin[2], Jessica Badlam[1], Ray Benza[1], Wendy Chung[2], Harrison Farber[1], Kathy Feldkircher[1], Bill Nichols[1], Abby Poms[1], Chang Yu[1], C Greg Elliott[1]

A52 DISCOVERY OF VASCULAR CELL-SPECIFIC EPIGENOMIC SIGNATURES, NOVEL TRANSCRIPTION FACTORS AND SIGNALING NETWORKS IN HUMAN PULMONARY ARTERIAL HYPERTENSION
Prakash Chelladurai[1], Carsten Künne[1], Christine Weber[2], René Reiner Nötzold[2], Mario Schmoranzer[1], Mario Looso[1], Uta-Maria Bauer[2], Werner Seeger[1], Soni Savai Pullamsetti[1]
1Max-Planck Institute for Heart and Lung Research, Bad Nauheim – 61231 – Germany, 2Institute of Molecular Biology and Tumor Research – Marburg – Germany

A53 PREVALENCE AND CLINICAL FEATURES OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 MUTATION IN KOREAN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS
Wook-Jin Chung[1], Jun Soo Lee[1], Seungbum Choi[1], Seyeon Oh[1], Hanul Cho[1], Kyung-Hee Kim[1], Kuk Hui Son[1], Hae Ok Jung[1], Jeongwon Ryu[1], Kyunghee Byun[1]
1Department of Cardiovascular Medicine, Gachon Cardiovascular Research Institute – Incheon – Korea, Republic of, 2Department of Cardiovascular Medicine, Gachon University Gil Medical Center – Incheon – Korea, Republic of, 3Department of Cardiology, Sejong General Hospital – Bucheon – Korea, Republic of, 4Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea – Seoul – Korea, Republic of

A54 FIRST IDENTIFICATION OF KRÜPPEL-LIKE FACTOR 2 MUTATION IN HERITABLE PULMONARY ARTERIAL HYPERTENSION
Christina Eichstaedt[1], Jie Song[1], Rebecca Rodríguez Viales[1], Zixuan Pani[1], Nicola Benjamin[1], Christine Fischer[1], Marius Hoeper[1], Silvia Ulrich[1], Katrin Hinderhofer[1], Ekkehard Grünig[1]
1Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg – Heidelberg – Germany, 2European Molecular Biology Laboratory – Heidelberg – Germany, 3Institute of Human Genetics, Heidelberg University – Heidelberg – Germany, 4Hannover Medical School, Clinic for Pneumology – Hannover – Germany, 5Clinic of Pulmonology, University Hospital Zurich – Zurich – Switzerland

A55 COMMON GENETIC BASIS FOR PULMONARY ARTERIAL HYPERTENSION AND HIGH ALTITUDE PULMONARY EDEMA
Christina Eichstaedt[1], Heimo Mairbäurl[2], Jie Song[1], Nicola Benjamin[1], Christine Fischer[1], Katrin Hinderhofer[1], Ekkehard Grünig[1]
1Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg – Heidelberg – Germany, 2Medical Clinic VII, Sports Medicine, University of Heidelberg and Translational Lung Research Centre Heidelberg (TLRC), German Centre for Lung Research (DZL) – Heidelberg – Germany, 3Institute of Human Genetics, Heidelberg University – Heidelberg – Germany

A56 CLINICAL MANIFESTATION OF HEREDITARY PULMONARY ARTERIAL HYPERTENSION BY A “SECOND HIT” MUTATION IN THE GENES BMPR2 AND EIF2AK4
Christina Eichstaedt[1], Jie Song[1], Rebecca Rodríguez Viales[1], Nicola Benjamin[1], Satenik Harutyunova[1], Christine Fischer[1], Katrin Hinderhofer[1], Ekkehard Grünig[1]
1Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg – Heidelberg – Germany, 2European Molecular Biology Laboratory – Heidelberg – Germany, 3Institute of Human Genetics, Heidelberg University – Heidelberg – Germany
POSTER SESSION

Tuesday, February 27, 2018

GENETICS AND GENOMICS

A57  LANDSCAPE OF MUTATIONS FOUND BY GENE PANEL ROUTINE SEQUENCING FOR PULMONARY HYPERTENSION

Mélanie Eyries*1, Anne Leroy*1, Barbara Girerd2, David Montani2, Marilyne Levy3, Damien Bonnet4, Arnaud Bourdin5, Romain Tresorier6, Ari Chauouet6, Vincent Cottin6, Céline Sanfrenzolo4, Grégoire Prevot6, Martine Reynaud-Gaubert1, Claire Dromer1, Ali Houiejji1,2, Marc Humbert1, Florent Soubrier1


A58  NOVEL CAUSATIVE GENES FOR HERITABLE PULMONARY ARTERIAL HYPERTENSION

Stefan Gräßl1, Matthias Haime1, Marta Bleda1, Charaka Hadinnapo1, Wei Li2, Joshua Hodgson3, Bin Liu3, Richard M Salmon1, Mark Southwood1, Laura Southgate1, Rajiv D Machado4, Jennifer M Martin1, Carmen M Treacy1, Katherine Yates1, Louise C Daugherty1, Olga Shamardina1, Deborah Whitehorn1, Simon Holden1, Micheala Aldred4, Harm J Bogaard5, Colin Church5, Gerry Coghlan5, Robin Condiffe5, Paul A Corris6, Cesare Danesino7, Mélanie Eyries1, Henning Galf1, Stefano Gio8, Hossein-Ardeschir Ghofrani5, J Simon R Gibbs5, Barbara Girerd2, Arjan C Houweling6, Luke Howard6, Marc Humbert21, David G Kiel6, Gabor Kovacs6, Robert V Mackenzie Ross5,7, Shahin Moledana1, David Montani21, Michael Newnham1, Andrea Olschewska5, Horst Olschewska1, Andrew J Peacock4, Joanna Pepke-Zaba5, Inga Prokopenko10, Christopher J Rhodes10, Laura Scelsi18, Werner Seeger18, Florent Soubrier14, Jay Suntharalingan17, Emilia Swietlik11, Mark R Toshner1, Anton Vonk Noordegraaf5, Quintin Waissfisz1, John Wharton5, Stephen J Wort18, Nicole Soranzo18, Willem H Ouweland11, Allan Lawrie11, Paul D Upton1, Richard C Trembath15, Martin R Wilkins10, Nicholas W Moores11

1University of Cambridge – Cambridge – United Kingdom, 2Papworth Hospital – Papworth – United Kingdom, 3Molecular and Clinical Sciences Research Institute, St George’s, University of London – London – United Kingdom, 4University of Lincoln – Lincoln – United Kingdom, 5Addenbrooke’s Hospital – Cambridge – United Kingdom, 6Cleveland Clinic – Cleveland, Ohio – United States of America, 7VU University Medical Center – Amsterdam – Netherlands, 8Golden Jubilee National Hospital – Glasgow – United Kingdom, 9Royal Free Hospital – London – United Kingdom, 10Imperial College London – London – United Kingdom, 11Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital – Sheffield – United Kingdom, 12King’s College London – London – United Kingdom, 13Wellcome Trust Sanger Institute – Hinxton – United Kingdom, 14University of Newcastle – Newcastle – United Kingdom, 15Department of Molecular Medicine, University of Pavia – Pavia – Italy, 16Département de génétique, hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, and UMR_S 1166-ICAN, INSERM, UPMC Sorbonne Universités – Paris – France, 17Royal United Hospitals Bath NHS Foundation Trust – Bath – United Kingdom, 18University of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL) and of the Excellence Cluster Cardio-Pulmonary System (ECCPS) – Giessen – Germany, 19Fondazione IRCCS Policlinico San Matteo – Pavia – Italy, 20National Heart & Lung Institute, Imperial College London – London – United Kingdom, 21Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay – AP-HP Service de Pneumologie, Centre de référence de l’hypertension pulmonaire; INSERM UMR_S 999, Hôpital Bicêtre, Le Kremlin-Bicêtre – Paris – France, 22Great Ormond Street Hospital – London – United Kingdom, 23Ludwig Boltzmann Institute for Lung Vascular Research – Graz – Austria
POSTER SESSION

Tuesday, February 27, 2018

GENETICS AND GENOMICS

A59  A SENSITIVE RESPONSE TO HYPOXIA IN PULMONARY ARTERY IN HIGH-ALTITUDE PULMONARY EDEMA SUSCEPTIBLE SUBJECTS UNDER A GENETIC BACKGROUND OF VARIATIONS IN THE EGLN1 GENE
Nobumitsu Kobayashi*, Fumiya Kinota, Yunden Droma, Toshimichi Horiiuchi, Atuhito Ushiki, Masanori Yasuo, Hiroshi Yamamoto, Masao Ota, Masayuki Hanaoka
Shinshu University School of Medicine – Matsumoto – Japan

A60  KCNK3 CHANNEL INACTIVATION LEADS TO PULMONARY VASCULAR ALTERATIONS IN RAT
Mélanie Lambert**, Aurélie Hautefort**, Boris Manoury[2], David Montani[3], Marc Humbert[1], Frédéric Perros[1], Fabrice Antigny[1]

PATHOPHYSIOLOGY OF THE RV AND OF THE PULMONARY CIRCULATION

A63  INHIBITION OF NITRIC OXIDE SYNTHASE UNMASKS POTENT VASOCONSTRICTION IN ESTABLISHED PULMONARY ARTERIAL HYPERTENSION
Kohtaro Abe*, Maniko Tanaka, Hiroyuki Tsutsui
Kyushu University Graduate School of Medical Sciences – Fukuoka – Japan

A64  DIMINISHED RIGHT VENTRICULAR FUNCTION AT DIAGNOSIS OF PULMONARY HYPERTENSION IS ASSOCIATED WITH MORTALITY IN BRONCHOPULMONARY DYSPLASIA
Gabriel Allt*, Shazia Bhombal, Jeffrey Feinstein, Theresa Tacy
Stanford University – Palo Alto – United States of America

A61  ENHANCED EXPRESSION OF ENDOTHELIN-2, AN ISOPLEPTIDE OF ENDOTHELIN-1, BY HYPOXIA IN LUNGS: POSSIBLE ROLE IN PULMONARY HYPERTENSION.
Yoko Suzuki[1], Ikeda Koji[2], Miyagawa Kazuya[3], Tamada Naoki[3], Nakayama Kauzuki[1], Yanagisawa Masashi[1], Emoto Noriaki[1]
[1]Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine – Kobe – Japan, [2]Clinical Pharmacy, Kobe Pharmaceutical University – Kobe – Japan, [3]International Institute for Integrative Sleep Medicine, University of Tsukuba – Tsukuba – Japan

A62  THE EFFECTS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 MUTATION ON RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION AFTER OPTIMAL COMBINATION THERAPY
Hiraide Takahiro*, Murata Mitsuhi*1, Kataoka Masaharu[1], Aimu Yuki[2], Isobe Sarasa[1], Wakawaki Takashi[1], Moriyama Hidenori[1], Endo Jin[1], Itabashi Yuji[1], Gamou Shinobu[2], Fukuda Keiichi[1]
[1]Department of Cardiology, Keio University School of Medicine – Tokyo – Japan, [2]Department of Laboratory Medicine, School of Medicine, Keio University – Tokyo – Japan, [3]Second Department of Internal Medicine, Kyorin University School of Medicine – Tokyo – Japan

A65  THE OMEGA-3 EPA:DHA 6:1 FORMULATION PREVENTS THE MONOCROTALINE-INDUCED PULMONARY HYPERTENSION, PULMONARY ARTERY REMODELING AND ENDOTHELIAL DYSFUNCTION, AND RIGHT VENTRICULAR FAILURE IN RATS
Said Amassi[1], Zahid Rasul Niaz[1], Mélanie Burbari[2], Romain Kessler[2], Mathieu Canuet[3], Florence Toli[3], Laurent Monassier[4], Nelly Boehm[3], Cyril Auger[3], Ferhat Meziani[2], Valérie Schini-Kerth[1]
Tuesday, February 27, 2018

PATHOPHYSIOLOGY OF THE RV AND OF THE PULMONARY CIRCULATION

A66 ALTERATION OF KCNK3 FUNCTION CONTRIBUTES TO RIGHT VENTRICULAR DYSFUNCTIONS IN EXPERIMENTAL PULMONARY HYPERTENSION
Fabrice Antigny[1], Mélanie Lambert[1], Angèle Boet[1], Catherine Rucker-Martin[1], Véronique Cajuano[1], Stéphane Haten[1], Aurélie Hautefort[1], Jean-Baptiste Michel[1], Dorfmuller Peter[1], Elie Fadel[1], Tom Kotsimbos[1], Philippe Jourdon[1], David Montani[2], Frédéric Perroil[1], Marc Humbert[1]

A67 IMPAIRED RIGHT VENTRICULAR O2 DELIVERY IS ASSOCIATED WITH REDUCED RIGHT VENTRICULAR RESERVE IN PULMONARY HYPERTENSION DURING EXERCISE
Zongye Cai*, Richard Wb Van Duin, Dirk Jan Duncker, Daphne Merkus
Erasmus MC – Rotterdam – Netherlands

A68 PULMONARY ARTERIAL VOLUME, A DETERMINANT OF RESERVOIR FUNCTION MAY MODULATE RIGHT VENTRICULAR PERFORMANCE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Hao-Chih Chang*, Lu Dai-Yin, Sung Shih-Hsien
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital – Taipei City – Taiwan

A69 ALTERED MYOCARDIAL ENERGY METABOLISM IN EXPERIMENTAL RIGHT VENTRICULAR FAILURE ON ACUTE AND CHRONIC INCREASED AFTERLOAD
Laurence Dewachter[1], Asmae Belhaj[2], Benoit Rondelet[2], Francois Kerbaul[1], Serge Brimioulle[1], Robert Naeije[1], Céline Dewachter[1]

A70 CORRELATION BETWEEN RIGHT VENTRICULAR FUNCTION ASSESSED BY ECHOCARDIOGRAPHY AND BY RIGHT HEART CATHETERIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION
Juan Farina[1], Augusto Lavalle Colbo[1], Hector Gomez Santa Maria[1], Diego Crippa[1], Brenda Varela[1], Alfredo Hirschson Prado[1], Alejandro Nitschel[1], Angeles Barth[1], Victor Daru[1], Adrian Lescano[1]

A71 PULMONARY VASCULAR RESISTANCE AND COMPLIANCE RELATIONSHIP IN PULMONARY HYPERTENSION: DIRECT MEASUREMENTS VERSUS EMPIRIC FORMULAE
Christian Gerges[1], Mario Gerges[1], Pierre Fesler[2], Anna Maria Pistriz[3], David Celermajer[1], Irene Lang[1]
[1]Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna – Vienna – Austria, [2]PhyMedExp, Department of Mountpellier, INSERM U1046, CNRS UMR 9214, and Department of Internal Medicine, Lapeyronie Hospital – Montpellier – France, [3]Department of Internal Medicine, Division of Cardiology, Ferrarotto Hospital, University of Catania – Catania – Italy, [4]Department of Cardiology, Sydney Medical School, University of Sydney – Sydney – Australia

A72 MIR-21 REGULATED RIGHT VENTRICULAR REMODELING SECONDARY TO PULMONARY ARTERIAL PRESSURE OVERLOAD
Chih-Hsin Hsu[1], Hao-Chih Chang[1], Frederick Y Chen[1], Ronglih Liao[1]

A73 ACTIVATED CONVENTIONAL DENDRITIC CELLS AS DRIVERS IN THE PATHOPHYSIOLOGY OF IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (IPAH)?
Thomas Koudstaal[1], Jennifer Van Huys[1], Tridib Das[1], Peter Heukeloe[1], Daphne Merkus[2], Michiel De Raaf[2], Ingrid Bergen[1], Bogaard Harmjarn[1], Caetano Reis E Sousa[1], Geert Van Loo[2], Rudi Hendriks[1], Karin Boomars[1], Mirjam Kool[1]

A74 EXERCISE HEMODYNAMIC PREDICTORS OF PEAK OXYGEN CONSUMPTION IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Eloara Machado Ferreira*, Carolina M S Messina, Rudolf K F Oliveira, Angelo X C Fonseca, Roberta P Ramos, Jaquelina S Ota-Arakaki
Federal University of São Paulo (UNIFESP) – São Paulo – Brazil

A75 POTENTIAL ROLE OF THE ARYL HYDROCARBON RECEPTOR IN PAH
Margaret Maclean*, Afshan Dean, Teja Gregorc, Craig Docherty
University of Glasgow – Glasgow – United Kingdom
POSTER SESSION

Tuesday, February 27, 2018

PATHOPHYSIOLOGY OF THE RV AND OF THE PULMONARY CIRCULATION

A76  OSTEOPONTIN IN RIGHT VENTRICULAR REMODELING
Arjen Mamazhakypov⁷, Akylbek Sydykov, Xia Tian, Kabita Pradhan, Astrid Weiß, Werner Seeger, Norbert Weismann, Ardeschir Ghofrani, Ralph Schermuly
Excellence Cluster Cardio-Pulmonary System, University of Giessen – Giessen – Germany

A77  THE STIFFNESS OF THE PULMONARY ARTERY AS A MARKER OF RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION
Olga Moiseeva*, Maria Simakova, Anton Rygkov, Aigun Kyzymly
Almazov National Medical Research Centre – Saint-Petersburg – Russian Federation

A78  THE CLINICAL VALUE OF ASSESSING RIGHT VENTRICULAR DIASTOLIC FUNCTION AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Hidenori Moriyama*, Toshimitsu Tsuig, Takashi Kawakami, Masaharu Kataoka, Takahiro Hiraide, Mai Kimura, Saras Isobe, Jin Endo, Takashi Kohno, Yuji Itabashi, Keiichi Fukuda
Keio University – Tokyo – Japan

A79  HIGH-SENSITIVE CARDIAC TROPONIN T LEVEL IS A SURROGATE MARKER FOR RV FUNCTIONAL RECOVERY AFTER SUCCESSFUL BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Mitsuhige Murata*, Toshimitsu Tsuig, Takahiro Hiraide, Hidenori Moriyama, Mai Kimura, Saras Isobe, Takashi Kawakami, Masaharu Kataoka, Takashi Kohno, Yuji Itabashi, Keiichi Fukuda

A80  WNT-SIGNALING PATHWAY DRIVES RIGHT VENTRICULAR REMODELING
Max-Planck-Institute for Heart and Lung Research – Bad Nauheim – Germany

A81  THE RELATIONSHIP BETWEEN PULMONARY BLOOD FLOW AND PULMONARY MICROVASCULAR RECRUITMENT IN SUPINE EXERCISING HUMANS
Stylianos Orfanos⁶, David Langleben⁴, Michele Giovinazzo⁵, Robert Schlesinger⁴, Fay Blenkhorn⁵, John Catravas⁵
²Jewish General Hospital – Montreal – Canada, ²²Ecklonion Hospital – Athens – Greece, ²²Old Dominion University – Norfolk – United States of America

A82  REGIONAL INHOMOGENEITY OF RIGHT VENTRICULAR CONTRACTION DURING HYPOXIC BREATHING BUT NOT DURING EXERCISE IN HEALTHY SUBJECTS
Beatrice Pezzuto*, Kevin Forton², Vitalie Faoro², Yoshiki Motoji², Roberto Badagliacca², Carmine Dario Vizza², Jean-Luc Vachiéry⁴²
²Free University of Brussels-Dept of Exercise Physiology of the Faculty of Motor Sciences; Sapienza University of Rome - Dept of Cardiovascular and Respiratory Sciences – Rome – Italy, ²²Free University of Brussels - Dept of Exercise Physiology of the Faculty of Motor Sciences; Erasme Academic Hospital - Dept of Cardiology - Brussels – Belgium, ²²Free University of Brussels - Dept of Exercise Physiology of the Faculty of Motor Sciences; Erasme Academic Hospital - Dept of Cardiology – Brussels – Belgium

A83  QUANTIFICATION AND VISUALIZATION OF PULMONARY VASCULAR RESPONSE TO NITRIC OXIDE USING COMPUTED TOMOGRAPHY
Farbod Rahaghi⁶, Tilo Winkler⁶, Kohila², Berta Marti², Fuster²,⁶ Ramya Radhakrishnan³, Tyler Blackwater³, James Ross³, Richard Channick³, R Scott Harris³, Raúl San José Estépar⁶, George Washko²⁵
²⁵Harvard Medical School, Brigham and Women’s Hospital – Boston – United States of America, ²²Harvard Medical School, Massachusetts General Hospital, Anesthesia, Critical Care and Pain Medicine – Boston – United States of America, ²²Harvard Medical School, Massachusetts General Hospital, Pulmonary and Critical Care – Boston – United States of America, ²²Harvard Medical School, Brigham and Women’s Hospital – Boston – United States of America, ²²Harvard Medical School, Brigham and Women’s Hospital, Department of Radiology – Boston – United States of America, ²²Harvard Medical School, Brigham and Women’s Hospital, Division of Pulmonary and Critical Care – Boston – United States of America

A84  ABNORMAL RESPONSE TO EXERCISE IN SYSTEMIC SCLEROSIS PATIENTS WITH NORMAL PULMONARY PRESSURES AT REST: A CASE-CONTROLLED STUDY
Asma Rimouche⁷, Sergio Caravita⁷, Laurence Dewachter², Antoine Bondue², Jean-Luc Vachiéry²
²²Erasme-ULB – Brussels – Belgium, ²²ULB – Brussels – Belgium
PATHOPHYSIOLOGY OF THE RV AND OF THE PULMONARY CIRCULATION

A85 ADAMTS8 PROMOTES THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION AND RIGHT VENTRICULAR FAILURE -A POSSIBLE NOVEL THERAPEUTIC TARGET-
Kimio Satoh*, Junichi Omura†, Nobuhiro Kikuchi†, Taiju Satoh†, Ryo Kurosawa†, Masamichi Nogi†, Shinshiro Sunamura†, Tomohiro Ohtsuki†, Elias Al-Mamuni†, Mohammad Abdul Hai Siddique†, Nobuhiro Yato†, Satoshi Miyata†, Yasushi Hoshikawa†, Yoshinori Okada†, Hiroaki Shimokawa†
†Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine – Sendai – Japan, †Department of Thoracic Surgery, Tohoku University Graduate School of Medicine – Sendai – Japan

A86 RIGHT VENTRICULAR CHARACTERISTICS IN EISENMENGER SYNDROME – ECG AND ECHO CORRELATIONS
Tatiana Valkovicova*, Monika Kaldararova†, Adriana Reptova†, Marcela Bohacekova†, Ljuba Bacharova†, Robert Hatala†, Iveta Simkova†
†Department of Cardiology and Angiology, Slovak Medical University and National Institute of Cardiovascular Diseases – Bratislava – Slovakia, †International Laser Center – Bratislava – Slovakia

A87 TRANSITION FROM POST- TO COMBINED PRE/POST-CAPILLARY PULMONARY HYPERTENSION: KEY ROLE OF ENDOTHELIN
Richard Wb Van Duin*, Kelly Starn†, Zongye Cai†, Dirk Jan Duncker†, Irwin Karl Reiss†, Daphne Merkus†
†Erasmus MC – Rotterdam – Netherlands, †Sophia Children’s hospital – Rotterdam – Netherlands

A88 PULMONARY HYPERTENSION IN TAKAYASU ARTERITIS
Ali Akdogan*, Esra Firat†, Yusuf Ziya Sener†, Berkcan Armanagari†, Metin Oksul†, Serkan Asil†, Vedat Hekimsoy†, Abdulsamet Erdener†, Alper Sari†
†Hacettepe University Faculty of Medicine, Department of Rheumatology – Ankara – Turkey, †Hacettepe University Faculty of Medicine, Department of Internal Medicine – Ankara – Turkey, †Hacettepe University Faculty of Medicine, Department of Cardiology – Ankara – Turkey

A89 A COMPARISON OF NT-ProBNP LEVELS IN PATIENTS WITH SSC-ASSOCIATED PAH AND PATIENTS WITH SSC-RELATED PH ASSOCIATED WITH LUNG DISEASE
Sahachat Aueyingsak*, Wilawan Khrisanapant, Upa Kukongviriyapan, Orapin Pasurivong, Burabha Pussadhamma
Faculty of Medicine, Khon Kaen University – Khon Kaen – Thailand

A90 RESULTS OF MEDIUM SEVEN YEARS’ FOLLOW-UP IN SYSTEMIC SCLEROSIS PATIENTS WITH EXERCISE INDUCED PULMONARY HYPERTENSION MEASURED DURING RIGHT HEART CATHETERIZATION
Luciana D’Angelo*, Andrea Garasca, Eleonora Bruschi, Francesco Musca, Oscar Massimiliano Epis, Antonella Moreo, Maria Frigerio
ASST Grande Ospedale Metropolitano Niguarda – Milan – Italy

A91 JOGJAKARTA CONGENITAL HEART DISEASE AND PULMONARY HYPERTENSION (COHARD-PH) STUDY: RESULTS FROM A SINGLE-CENTER NATIONAL REFERRAL HOSPITAL REGISTRY IN INDONESIA
Lucia Kris Dinarti*, Dyah Wulan Anggraini, Anggoro Budi Hartopo
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Gadjah Mada - Dr Sardjito Hospital – Yogyakarta – Indonesia
Tuesday, February 27, 2018

PH HAEMODYNAMIC DEFINITIONS AND CLINICAL CLASSIFICATIONS AND CHARACTERISTICS OF SPECIFIC PAH SUBGROUPS

A92  THE MORTALITY OF PREGNANT PATIENTS WITH UNCORRECTED ATRIAL SEPTAL DEFECT IS INFLUENCED BY SEVERE PULMONARY HYPERTENSION – A SUBSTUDY OF JOGJAKARTA COHARD-PH REGISTRY
Anggoro Budi Hartopo*, Dyah Wulan Anggrahini, Lucia Kris Dinarti
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Gadjah Mada – Yogyakarta – Indonesia

A93  PULMONARY HYPERTENSION IN ASIA: INSIGHTS FROM AN ASIAN TERTIARY REFERRAL CENTRE
Teng Yik Hoo*,[1], Benjamin Chew[1], Jonathan Yap[1], Wen Ruan[1], Jeremy Teoh[1], Maggie Wong[1], Sewa Du Wei[1], Ghee Chee Phua[1], Andrea Low[1], Ju Le Tan[2], Soo Teik Lim[1]

A94  THE DISPROPORTIONAL INCREASE OF PULMONARY PRESSURE IS RELATED TO THE CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE
Wei-Ming Huang*, Shih-Hsien Sung
Taipei Veterans General Hospital – Taipei – Taiwan

A95  THE DETERMINANTS OF “OUT OF PROPORTION” PULMONARY HYPERTENSION IN PATIENTS WITH MILD CHRONIC OBSTRUCTION PULMONARY DISEASE
Wei-Ming Huang*, Shih-Hsien Sung
Department of Medicine, Taipei Veterans General Hospital – Taipei – Taiwan

A96  IMPACT OF BLOOD VISCOSITY ON PULMONARY VASCULAR RESISTANCE IN PATIENTS ASSESSED FOR PULMONARY HYPERTENSION AT A LARGE TERTIARY CENTRE
Aleksander Kempny*, Konstantinos Dimopoulos, Colm Mccabe, Rafael Alonso-Gonzalez, Laura Price, Michael Gatzioulis, Stephen J Wort
Royal Brompton Hospital – London – United Kingdom

A97  GENDER ASPECTS AMONG PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION IN THE MODERN TREATMENT ERA
Barbro Kjellström*, Clara Hajlmarsson[2], David Kylanhammer[3], Sven-Erik Bartfay[4], Göran Rådegran[5], Magnus Nisel[6]

A98  CHARACTERISTICS OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ANTICENTRIOLE AUTOANTIBODIES
Kana Kubota*
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo – Bunkyo-ku, Tokyo – Japan

A99  PH EXPERIENCE IN A TERTIARY CENTER
Mehmet Serdar Kucukoglu*, Mert Palabiyik, Ozge Cetinarslan, Rengin Demir
Istanbul University Institute of Cardiology – Istanbul – Turkey

A100  PULMONARY HYPERTENSION IN GREECE: PRELIMINARY DATA FROM A NATIONAL REGISTRY
Athanasios Manginas*, Maria Toupourlekal*, George Giannakoulas[1], Sophia-Anastasia Mouratoglou[1], Haralambos Karvounis[1], Effitina Demouret[2], Panagiotsi Karifilli[2], Georgios Athanasopoulos[2], Spyridon Rammos[2], Iraklis Tsangaris[3], Elef Stagaki[3], Stylianos Orfanos[3], Georgia Pitsiou[3], Evangelia Panagiotidou[3], Ioanna Mitrouski[3], Ekaterini Avgiropoulou[3], Katerina Nak[3], Stavros Konstandinides[3], Anastasia Anth[3]
POSTER SESSION

Tuesday, February 27, 2018

PH HAEMODYNAMIC DEFINITIONS AND CLINICAL CLASSIFICATIONS AND CHARACTERISTICS OF SPECIFIC PAH SUBGROUPS

A101 PREVALENCE AND CORRELATES OF OBESITY IN PRECAPILLARY PULMONARY HYPERTENSION


A102 ECHOCARDIOGRAPHIC ASSESSMENT OF RIGHT VENTRICULAR COUPLING TO PULMONARY CIRCULATION IS ASSOCIATED WITH HEMODYNAMIC DISEASE SEVERITY IN PRECAPILLARY PULMONARY HYPERTENSION


A103 THE BLOOD COUNT LEVELS, THE MEAN PULMONARY ARTERY PRESSURE AND SIX MINUTE WALK TEST AMONG ADULT FILIPINOS WITH PULMONARY HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASES: RESULTS FROM THE PHILIPPINE HEART CENTER – CENTER FOR PULMONARY VASCULAR DISORD
Maria Paz Matero*
Philippine Heart Center – Quezon City – Philippines

A104 COMPARISON OF CARDIAC OUTPUT DETERMINATION BY THE INDIRECT FICK AND THE THERMODILUTION METHOD IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Sophia Anastasia Mouratoglou*, Ioannis Doundoulakis, Feloukidis Cristos, Bazmpari Maria Anna, Arvanitaki Alexandra, Toupourleka Maria, Grosmanidis Vasileios, Hadjimitiades Stavros, Karvounis Haralampos, Giannakoulas George
First Department of Cardiology, AHEPA University Hospital of Thessaloniki – Thessaloniki – Greece

A105 PULMONARY ARTERIAL HYPERTENSION IN IGG4-RELATED DISEASE: ALL ABOUT THE EPOPROSTENOL?
Nicole Ruopp*, Harrison Farber
Boston University – Boston – United States of America

A106 PULMONARY ARTERY DILATATION PROGRESS IN PATIENTS WITH PULMONARY HYPERTENSION COEXISTING PULMONARY ARTERY ANEURYSM. -POSSIBLE INVOLVEMENT OF PROSTAGLANDIN E RECEPTOR TYPE 4 OVEREXPRESSION-Akagi Satoshi[1], Nakamura Kazufumi[1], Yokoyama Utako[2], Kasahara Shingo[2], Sarashina Toshihiro[1], Eiji Kentaro[1], Ito Hiroshi[1]

[1]Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – Okayama – Japan, [2]Department of Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine – Yokohama – Japan, [3]Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – Okayama – Japan
POSTER SESSION

Tuesday, February 27, 2018

PH HAEMODYNAMIC DEFINITIONS AND CLINICAL CLASSIFICATIONS AND CHARACTERISTICS OF SPECIFIC PAH SUBGROUPS

A107 DIFFERENTIAL INCREASE IN CIRCULATING PAN VEGF-A AND VEGF-A165B LEVELS AMONG SUBTYPE OF PULMONARY HYPERTENSION
Shimokata Shigetake*, Kikuchi Ryosuke, Adachi Shiro, Okumura Naoki, Okumura Taeji, Tajima Fumitaka, Kamimura Yoshihiro, Nakano Yoshihisa, Kondo Takahisa, Murohara Toyoaki
1Department of Cardiology, Nagoya University Graduate School of Medicine – Nagoya – Japan, 2Department of Medical Technique, Nagoya University Hospital – Nagoya – Japan, 3Department of Advanced in Cardiopulmonary Disease, Nagoya University Graduate School of Medicine – Nagoya – Japan

A108 SEVERE PULMONARY ARTERIAL HYPERTENSION IN PATIENTS TREATED BY CHINESE HERB NATURE INDIGO: QING-DAI
Yuichi Tamura*, Asuka Furukawa, Ly Tu, Christophe Guignabert, Marc Humbert, Noriaki Emoto, Hiroshi Watanabe, Koichiro Tatsumi
1IUHW Mita Hospital ~ Tokyo ~ Japan, 2South Paris University ~ Paris ~ France, 3Kobe University ~ Kobe ~ Japan, 4Hamamatsu University School of Medicine ~ Hamamatsu ~ Japan, 5Chiba University ~ Chiba ~ Japan

A109 CLINICAL CHARACTERISTICS AND SURVIVAL OF ASIAN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Jonathan Yap*, Teng Yik Hoo, Jeremy Teoh, Benjamin Chew, Doo Wen Sewa, Ghee Chee Phua, Andrea Low, Choong Hee Lim, Ju Le Tan, Maggie Wong, Wen Ruan
1Department of Respiratory Medicine, Singapore General Hospital – Singapore – Singapore, 2Department of Cardiology, National Heart Centre Singapore – Singapore – Singapore, 3Department of Rheumatology, Singapore General Hospital – Singapore – Singapore

A110 THE STRUCTURAL-FUNCTIONAL STATE OF THE SYSTEMIC CIRCULATION ARTERIES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Iryna Zhyvilo*, Yuri Sirenko, Ganna Radchenko
SI «National Scientific Centre «M. D. Strazhesko Institute of Cardiology» of NAMS of Ukraine» ~ Kyiv ~ Ukraine

A111 DEATH OR RESOLUTION: THE NATURAL HISTORY OF PULMONARY HYPERTENSION IN BRONCHOPULMONARY DYSPLASIA
Gabriel Altit*, Shazia Bhombal, Theresa Tacy, Jeffrey Feinstein
Stanford University ~ Palo Alto ~ United States of America

A112 RECEPTOR TYROSINE KINASES AND RELATED LIGANDS PROVIDE NEW PLASMA BIOMARKERS IN PULMONARY ARTERIAL HYPERTENSION
Habib Bouzina*
– Sweden

A113 NONSYNDROMIC PERIPHERAL PULMONARY ARTERY STENOSIS IS ASSOCIATED WITH HOMOZYGOSITY OF RNF213 P.Arg4810Lys REGARDLESS OF CO-OCCURRENCE OF MOYAMOYA DISEASE
Sung-A Chang*, Ju Sun Song, Taek Kyoo Park, Jung Hoon Yang, Woo Chan Kwon, So Ree Kim, Sung Mok Kim, Jihoon Cha, Shin Yi Jiang, Young Seok Cho, Tae Jung Kim, Oh Young Bang, Jin Young Song, Chang Seok Ki, Duk-Kyung Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine ~ Seoul ~ Korea, Republic of

A114 CLINICAL PROFILING AND PREDICTING CLINICAL DETERIORATION IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS IN A PULMONARY HYPERTENSION REFERENCE CENTER IN CAMPINAS-BRAZIL
Mônica Corso Pereira*, Plinio José Whitaker Wolf
1Faculty of Medical Sciences of the State University of Campinas (Unicamp) ~ Campinas ~ Brazil, 2Student of the Faculty of Medicine of Pontifical Catholic University of Campinas (Puccamp) ~ Campinas ~ Brazil
Tuesday, February 27, 2018

DIAGNOSIS OF PULMONARY HYPERTENSION

**A115** INCIDENCE OF PULMONARY HYPERTENSION AND DETERMINING FACTORS IN PATIENTS WITH SYSTEMIC SCLEROSIS AFTER NEGATIVE RIGHT HEART CATHETERISATION

Satnenik Harutyunova*, Gerr Coghlan, Matthias Wolf, Oliver Distler, Christopher P Denton, Martin Doelberg, Alberto Marra, Nicola Benjamini, Christine Fischer, Ekkehard Grünig

1Cardiology Department, Royal Free Hospital, London – London – United Kingdom, 2Centre for Pulmonary Hypertension, Thoracclinic at the University Hospital Heidelberg – Heidelberg – Germany, 3Department of Rheumatology, Faculty of Medicine, University of Zurich – Zurich – Switzerland, 4Centre of Rheumatology, Royal Free Hospital, London – London – United Kingdom, 5Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland – Allschwil – Switzerland, 6Institute of biostatistics University clinic Heidelberg – Heidelberg – Germany

**A116** PULMONARY HYPERTENSION IN ASIA: ESTIMATED PREVALENCE AND PROGNOSIS FROM THE ECHOCARDIOGRAPHY COHORT

Chih-Hsin Hsu, Wei-Ting Chang, Hsiang-Yuan Chang, Wei-Shin Liu, Wei-Da Lu

1Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Yungkang Dist – Tainan – Taiwan, 2Department of Internal Medicine,National Cheng Kung University – Tainan – Taiwan, 3National Cheng Kung University Hospital Dou-Liou Branch – Dou-Liou – Taiwan, 4Tzu Chi General Hospital – Hualien – Taiwan

**A117** PREVALENCE OF PULMONARY HYPERTENSION IN PATIENTS WITH SARCOIDOSIS: A SINGLE CENTER EXPERIENCE

Deniz Kaptan Ozen, Bulent Mutlu, Alper Kepez, Derya Kocakaya, Berrin Ceyhan, Batur Gonenc Kanar, Okan Erdogan, Halil Atas

1Marmara University Medical Faculty Cardiology Department – ISTANBUL – Turkey, 2Marmara University Medical Faculty Pneumology Department – ISTANBUL – Turkey

**A118** EFFICIENT DETECTION OF PULMONARY ARTERIAL HYPERTENSION USING SERUM HAPTOGLOBIN LEVEL AND CARDIAC MRI IN PATIENTS WITH CONNECTIVE TISSUE DISEASES

Masaru Kato, Hiroyuki Nakamura, Eri Sugawara, Yuichiro Fujieda, Kenji Oku, Toshiyuki Bohgaki, Shinuke Yasuda, Hiroshi Ohira, Ichizo Tsujino, Masaharu Nishimura, Tatsuya Atsumi

1Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University – Sapporo – Japan, 2First Department of Medicine, Hokkaido University Hospital – Sapporo – Japan

**A119** NAILFOLD VIDEOMICROSCOPY PARAMETERS AS A PREDICTORS OF PULMONARY ARTERIAL HYPERTENSION DEVELOPMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS

Nataliya Klyaus, Maria Simakova, Kirill Malikov, Alexey Maslyanskii, Olga Moiseeva

Federal State Budgetary Institution “V.A. Almazov National Medical Research Center” of the Ministry of Health of the Russian Federation – Saint-Petersburg – Russian Federation

**A120** ACCURACY AND PRECISION OF MEAN PULMONARY PRESSURE ASSESSED BY ECHOCARDIOGRAPHY AMONG PATIENTS WITH PULMONARY HYPERTENSION

Adrian Lescano, Juan Farina, Hector Gomez, Santa Maria, Augusto Lavalle Cobo, Guadalupe Romero, Nicolas Gonzalez, Miguel Gonzalez, Victor Daru, Hugo Granelli

Finochietto Clinic – Buenos Aires – Argentina

**A121** RAISING PAH AWARENESS IN SERBIA

Senka Milutinov*, Ilija Andrijevic, Jovan Matijasevic, Ana Andrijevic

Institute for Pulmonary Diseases of Vojvodina – Sremska Kamenica – Serbia

**A122** RIGHT HEART CATHETERIZATION FOR THE ASSESSMENT OF PULMONARY HYPERTENSION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE

Nesrin Mogulkoc, Hakan Kultursay, Bahri Akdeniz

1Ege University Hospital Pulmonology Department – Izmir – Turkey, 2Ege University Hospital, Cardiology Department – Izmir – Turkey, 3Dokuz Eylul University Hospital, Cardiology Department – Izmir – Turkey

**A123** EVALUATION OF CARDIAC FUNCTIONAL ALTERATIONS AND NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH SYSTEMIC SARCOIDOSIS

Bulent Mutlu, Deniz Kaptan Ozen, Alper Kepez, Derya Kocakaya, Berrin Ceyhan, Okan Erdogan, Batur Gonenc Kanar, Halil Atas

1Marmara University Medical Faculty Cardiology Department – ISTANBUL – Turkey, 2Marmara University Medical Faculty Pneumology Department – ISTANBUL – Turkey
## POSTER SESSION

**Tuesday, February 27, 2018**

### DIAGNOSIS OF PULMONARY HYPERTENSION

<table>
<thead>
<tr>
<th>A124</th>
<th>THE CONTRIBUTION OF ENDOTHELIAL CELLS TO THE VOLATOLOMIC SIGNATURE OF PAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morad Nakhleh*[1], Salam Khatib[2], Ly Tu[1], Maria Vinhas[1], Barbara Girerd[1], Frederic Ferro[1], David Montani[1], Raneen Jeries[2], Peter Dorfmuller[1], Elie Fadel[1], Christophe Guignabert[1], Marc Humbert[1], Hossam Haick[2], Sylvia Cohen-Kaminsky[1]</td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>A125</th>
<th>CONGENITAL HEART DISEASES: A RARE REASON FOR PULMONARY HYPERTENSION IN ADULT PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gulfer Okumus*[1], Celik Sumer[1], Zuleyha Bingol[1], Gokcen Orhan[2], Murat Inanc[3], Ahmet Kaya Bilge[1]</td>
<td></td>
</tr>
</tbody>
</table>

[1]Istanbul University Medical Faculty Department of Pulmonary Diseases – Istanbul – Turkey. [2]Siyami Ersek Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Department of Cardiovascular Surgery – Istanbul – Turkey. [3]Istanbul University Medical Faculty Department of Rheumatology – Istanbul – Turkey. [1]Istanbul University Medical Faculty Department of Cardiology – Istanbul – Turkey

<table>
<thead>
<tr>
<th>A126</th>
<th>TUMOR MARKERS ARE ALTERED IN PLASMA FROM PULMONARY ARTERIAL HYPERTENSION PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Göran Rådegran*[1], Habib Bouzina[2]</td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>A127</th>
<th>PULMONARY HYPERTENSION (PH) DUE TO LEFT HEART DISEASE: A PREDICTIVE MODEL USING THE NATIONAL ECHO DATABASE OF AUSTRALIA (NEDA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Strange*[1], David Playford[1], Jim Codde[2], David Celermajer[2], Gregory Scalia[3], Kevin Chung[1]</td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>A128</th>
<th>CT FUNCTIONAL PARAMETERS FOCUSING ON RVOT FOR PH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi-Shan Tsai*[1], Hsu Chih-Hsin[2]</td>
<td></td>
</tr>
</tbody>
</table>

[1]Department of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – Tainan – Taiwan. [2]Department of Diagnostic Radiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – Tainan – Taiwan
Wednesday, February 28, 2018

RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION

B10 Efficacy of oral iron substitution in nonanemic-iron deficient PAH patients
Bahri Akdeniz*, Ebru Özpelit, Dilek Sezgin, Bihter Sentürk, Can Sevîng, Resit Yigit Yilancioglu, Nezihi Baris
No ~ İzmir ~ Turkey

B11 How efficacious is the guideline based risk stratification in whole PAH population in routine practice?
Bahri Akdeniz*, Ebru Özpelit, Dilek Sezgin, Can Sevîng, Nezihi Baris, Bihter Sentürk
No ~ İzmir ~ Turkey

B12 Relationship between balance and exercise capacity in patients with pulmonary arterial hypertension
Bahri Akdeniz*, Buse Ozcan Kahraman, Sema Savci, Ismail Ozsoy, Serap Acar, Ebru Özpelit, Can Sevinc
Dokuz Eylül University ~ İzmir ~ Turkey

B13 Role of cardiac magnetic resonance in stratifying the prognosis of patients with pulmonary arterial hypertension
Alessandra Albini*, Fabio Dardi, Massimiliano Palazzini, Enrico Gotti, Andrea Rinaldi, Enrico Monti, Elisa Zuffa, Filippo Pasca, Nikita Tanese, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Galie
University of Bologna, Department of Specialized Diagnostic and Experimental Medicine ~ DIMES - Bologna/IT ~ Bologna ~ Italy

B14 Transition from subcutaneous treprostinil to intravenous thermostable epoprostenol in patients with severe pulmonary arterial hypertension
Anastasia Anthi*, Konstantina Ntaï, Dimitrios Konstantonis, Frantzeska Frantzeskaki, Eleni斯塔γki, Cornelia Mitaraki, Athanasios Pappa, Michalis Rizos, Olympia Apostolopoulou, Apostolos Agamanidis, Stylianos Orfanos
Pulmonary Hypertension Clinic and 2nd Department of Critical Care, University of Athens, ‘Attikon’ Hospital ~ Athens ~ Greece, Pulmonary Hypertension Clinic, University of Athens, ‘Attikon’ Hospital ~ Athens ~ Greece

B15 Initial treatment strategy and long-term survival in pulmonary arterial hypertension (PAH)
Athénaïs Boucly*, Jason Weatherald, Laurent Savale, David Montani, Xavier Jais, Mitja Jevnikar, Gérald Simonneau, Marc Humbert, Olivier Sibilon
1) Université Paris-Sud, APHP, Hôpital Bicêtre – Le Kremlin-Bicêtre – France; 2) Department of Medicine, Division of Respiratory, University of Calgary ~ Calgary, AB ~ Canada

B16 Long-term outcomes and predictors of survival in patients with pulmonary arterial hypertension without access to parenteral prostanoïd therapy
Elena Dimitrova*, Arman Postadzhiyan, Bozhidar Finkov, Blagorodna Karatancheva, Emilia Nasevá, Vasil Velchev
1) National Heart Hospital ~ Sofia ~ Bulgaria; 2) University Hospital "Saint Anna" ~ Sofia ~ Bulgaria; 3) Medical University - Sofia ~ Sofia ~ Bulgaria

B17 Improvement of pulmonary diffusion capacity after intravenous iron substitution in patients with iron deficiency and pulmonary hypertension
Daniel Dumitrescu*, Tilmann Kramer, Henrik Hagmanns, Felix Gerhardt, Thomas Viethen, Stephan Baldus, Stephan Rosenkranz
Zentrum der Universität zu Köln ~ Cologne ~ Germany

B18 Correlates of WHO functional class in patients with pulmonary arterial hypertension associated with congenital heart disease. Results from challenge registry.
Christos Feloukidis*, George Giannakoulas, Konstantinos Vasiliadis, Alexandra Frogoudaki, Christos Ntellos, Afroditi Tzifa, Styliani Brili, Athanasios Manginas, Despina Ntoudi, Marios Kolios, Antonios Pitsis, Haralampos Karvounis, Konstantinos Tsoufis, Spyridon Rammoss
1) Cardiology Department, AHEPA University Hospital ~ Thessaloniki ~ Greece; 2) Cardiology Department, General Hospital of Piraeus ~ Athens ~ Greece; 3) Cardiology Department, Attikon University Hospital ~ Athens ~ Greece; 4) Cardiology Department, Hippokration University Hospital ~ Athens ~ Greece; 5) Cardiology Department, University Hospital of Ioannina ~ Ioannina ~ Greece; 6) Cardiology Department, Saint Luke’s Clinic ~ Thessaloniki ~ Greece; 7) Cardiology Department, Department of Paediatric Cardiology and ACHD, Onassis Cardiac Surgery Centre ~ Athens ~ Greece; 8) Department of Congenital Heart Disease, Mitera Children’s Hospital ~ Athens ~ Greece
POSTER SESSION

Wednesday, February 28, 2018

RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION

B19  EXERCISE CMR TO EVALUATE RV FUNCTION AND HEMODYNAMICS IN PAH: PILOT STUDY
Veronica Franco*, Eks Wye Pollock, Subha Raman
The Ohio State University – Columbus, Ohio – United States of America

B20  INVESTIGATION OF HEPATIC FIBROSIS AS A NOVEL PROGNOSTIC FACTOR IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Asuka Furukawa*, Yuichi Tamura
International University of Health and Welfare Mita Hospital – Tokyo – Japan

B21  AUDIT OF DISEASE TARGETED THERAPIES IN ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

B22  SAFETY OF SWITCHING TO RIOCIUGAT FOR THE TREATMENT OF PULMONARY HYPERTENSION: DATA FROM THE EXPERT REGISTRY
POSTER SESSION

Wednesday, February 28, 2018

RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION

B23 RISK STRATIFICATIONS AND DEATHS IN ADULT UNCORRECTED ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION: AN INDONESIAN EXPERIENCE
Anggoro Budi Hartopo*, Dyah Wulan Anggraini, Lucia Kris Dinarti
Department of Cardiology and Vascular Medicine Universitas Gadjah Mada/Sardjito General Hospital – Yogyakarta – Indonesia

B24 INITIAL COMBINATION THERAPY WITH RIOCIUGAT AND AMBIRESITAN IN PULMONARY ARTERIAL HYPERTENSION: A PROSPECTIVE OPEN-LABEL STUDY
Naushad Hirani*, Jason Weatherald, Doug Helmersen, Mitesh Thakrar, Rhea Varughese, Carmen Lydell, Nowell Fine
University of Calgary – Calgary – Canada

B25 IMPACT OF AGE AND COMORBIDITY ON OUTCOME IN IDIOPATHIC PULMONARY HYPERTENSION: DATA FROM THE SWEDISH PULMONARY ARTERIAL HYPERTENSION REGISTRY
Clara Hjalmarsson*¹, Göran Rådegran², David Kyllhammar², Bengt Rundqvist², Jonas Mårtensson³, Magnus Nisell¹, Barbro Kjellström⁴
¹Department of Clinical Sciences, Cardiology, Lund University and Skåne University Hospital – Lund – Sweden, ²Department of Cardiology, Sahlgrenska Academy, Gothenburg University, and Sahlgrenska University Hospital – Göteborg – Sweden, ³Department of Clinical Physiology and Department of Medicine and Health Sciences, Linköping University – Linköping – Sweden, ⁴Cardiology Unit, Department of Medicine, Karolinska Institute – Stockholm – Sweden

B26 EFFICACY AND SAFETY OF EARLY SEQUENTIAL COMBINATION THERAPY WITH RIOCIUGAT AND ENDOTHELIN RECEPTOR ANTAGONISTS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM PATENT-1 AND PATENT-2
Marc Humbert¹,², Ekkehard Grünig²,³, Pavel Jansal³, Gérald Simonneau¹, Frantík Rahaghi⁴, Stephen Rosenkranz⁵, Dennis Busse⁶, Christian Meier⁷, Janethe De Oliveira Pena⁸, Hossein-Ardeschir Ghofrani²,³
¹Université Paris-Sud, Le Kremlin-Bicêtre, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre – Le Kremlin-Bicêtre – France, ²Centre for Pulmonary Hypertension, Thoracoclinic at Heidelberg University Hospital – Heidelberg – Germany, ³Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University – Prague – Czech Republic, ⁴Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Florida, Weston – Florida – United States of America, ⁵Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC), Cologne University Heart Center – Cologne – Germany, ⁶Chrestos Concept GmbH & Co. KG – Essen – Germany, ⁷Bayer AG, Global Development, Global Medical Affairs – Berlin – Germany, ⁸Bayer HealthCare Pharmaceuticals Inc, Whippany – New Jersey – United States of America, ⁹University of Giessen and Marburg Lung Center (UMLC), Giessen, Germany, member of the German Center for Lung Research (DZL) – Giessen – Germany

B27 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INFLAMMATORY MARKERS IN PREDICTION OF LONG-TERM RESPONSIVENESS TO CALCIUM CHANNEL BLOCKERS IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
Kamil Janast*, Marcin Waligora, Wojciech Magon, Jakub Stepieniewski, Piotr Podolec, Grzegorz Kopeč
Department of Cardiac and Vascular Diseases Jagiellonian University Medical College – Krakow – Poland

B28 OUTCOME OF COMPRESSION OF LEFT CORONARY ARTERY IN PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASES
Jo Won Jung*, Sang Eun Lee, Hyuk-Jae Chang, Se Yong Jung, Jae Young Choi, Yu Lim Shin, Han Ki Park, Young Hwan Park
Yonsei University College of Medicine – Seoul – Korea, Republic of

B29 EARLY EXPERIENCE OF MACITENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN CONGENITAL HEART DISEASES IN SINGLE CENTER.
Jo Won Jung*, Hyeok Jae Chang, Se Yong Jung, Jae Young Choi
Yonsei University College of Medicine – Seoul – Korea, Republic of

B30 CLINICAL COURSE OF INITIAL ORAL COMBINATION THERAPY FOR THE TREATMENT OF PAH IN SYSTEMIC SCLEROSIS
Yasushi Kawaguchi*, Yuki Ichimura, Tomoaki Higuchi, Kae Takagi
Institute of Rheumatology, Tokyo Women’s Medical University – Tokyo – Japan

B31 RAPID SEQUENTIAL COMBINATION THERAPY WITH PDE5 INHIBITORS AND ENDOTHELIN RECEPTOR ANTAGONISTS SUBSTANTIALLY IMPROVES HEMODYNAMICS AT EARLY FOLLOW-UP
Tilmann Kramer*, Daniel Dumitrescu, Felix Gerhardt, Philipp Nattmann, Christopher Hohmann, Stephan Baldus, Stephan Rosenkranz
Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Germany – Cologne – Germany

B32 FUTURE DIRECTIONS OF ANTHROPOLOGICAL PULMONARY HYPERTENSION RESEARCH
Anjali R. Prasad, Neeraj K. Prasad
University of Texas A&M, College Station – Texas – United States of America

B33 ROLE OF PROTEIN EXPOSURE AND INFLAMMATION IN THE DEVELOPMENT OF PULMONARY HYPERTENSION
Karl A. Reiling*, Brian L. Wold, Elizabeth M. Cleland
Department of Pediatrics, University of Minnesota – Minneapolis – Minnesota – United States of America
B32  HEMODYNAMIC AND HISTOPATHOLOGIC BENEFITS OF EARLY TREATMENT WITH MACITENTAN IN A RAT MODEL OF PULMONARY ARTERIAL HYPERTENSION  
Kim Kyung-Hee*[2], Kim Hyung-Kwan[1]

[1]Seoul National University Hospital – Seoul – Korea, Republic of  
[2]Sejong General Hospital – Kyunggi-do – Korea, Republic of

B33  THE PROGNOSTIC VALUE OF DLCO AND PULMONARY BLOOD FLOW IN PATIENTS WITH PULMONARY HYPERTENSION  
Tobias Lange*, Nicoletta Mergenthaler

University Medical Center Regensburg – Regensburg – Germany

B34  PULMONARY HYPERTENSION IN KOREAN PATIENTS WITH CONNECTIVE TISSUE DISEASE: RESULTS FROM EXTENDED FOLLOW-UP OF A NATION-WIDE REGISTRY  
Shin-Seok Lee*[1], Chan Hong Jeon[1], Han Ki Park[1]

[1]Soonchunhyang University Hospital – Bucheon – Korea, Republic of  
[2]Chonnam National University Bighteul Hospital – Gwangju-Gwangyang – Korea, Republic of  
[3]Severance Hospital, Yonsei University College of Medicine – Seoul – Korea, Republic of

B35  FUNCTIONAL CAPACITY USING SUBMAXIMAL EXERCISE TEST IS RELIABLE PREDICTOR FOR AGGRAVATION OF PULMONARY HYPERTENSION  
Byeong-Ju Lee*, Jung Hyun Choi

Pusan national university hospital – Busan – Korea, Republic of

B36  CLINICAL EFFICACY OF MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: OUR EXPERIENCE IN ARGENTINA  
Adrián Lescano*[1], Nicolás Atamanúlik[2], Vanesa Gregorietti[2], Nicolás Caruso[2], Daniela García Brascia[2], María Lorena Corone[2], Juan Farina[2], Sergio Perrone[1], Guillermo Bortman[1]

[1]Finochietto Clinic – Buenos Aires – Argentina  
[2]Hospital El Cruce – Buenos Aires – Argentina  
[3]Hospital Italiano – Cordoba – Argentina  
[6]Instituto Cabrall – Comientes – Argentina

B37  MEDICATION ADHERENCE AND RISK OF HOSPITALIZATION IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDEIS)  
Cassandra Lickert*[1], Jerrold Hill[2], Michele Cole[3], Rolin Wade[2], Yuen Tsang[1], William Drake[1]


38  SURVIVAL OF PATIENTS WITH PULMONARY HYPERTENSION - A SINGLE CENTER EXPERIENCE IN JAPAN-
Hiromi Matsubara*, Aiko Ogawa

National Hospital Organization Okayama Medical Center – Okayama – Japan

B39  MORTALITY IN PULMONARY ARTERIAL HYPERTENSION TRIALS: A COMPARISON BETWEEN META-ANALYSES  
Enrico Monti*, Massimiliano Palazzini, Enrico Gotti, Fabio Dardi, Andrea Rinaldi, Alessandra Albini, Elisa Zuffa, Daniele Guarino, Filippo Pasca, Nikita Tanese, Antonio Colangelo, Mariangela Rotunno, Alessandra Manes, Nazzareno Galie

University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT – Bologna – Italy

B40  PROGNOSTIC VALUE OF 12-LEAD ECG IN PATIENTS WITH PRECAPILLARY PULMONARY HYPERTENSION  
Thomas Nguyen*, Jean-Luc Vachier, Rubén Casado-Arroyo
Erasmus University Hospital, Department of Cardiology – Brussels – Belgium

B41  ALLERGIC TO ONE DOES NOT MEAN TO ALL  
Zeki Ongen*, Burçak Kiliçkiran Avci, Hurrem Gul Ongen
Cerrahpasa Medical Faculty – Istanbul – Turkey

B42  CARDIOPULMONARY EXERCISE TEST IN PULMONARY ARTERIAL HYPERTENSION PATIENTS: LONGITUDINAL CHANGES IN THE MODERN MANAGEMENT ERA  
Evangelia Panagiotidou*[1], Georgia Pitsiou[2], Evdokia Sourla[2], Sofia Akrithidou[2], Vasilios Bagalas[2], Afroditi Boutou[2], Ioannis Stanopoulos[2]

[1]Respiratory Failure Clinic, General Hospital of Thessaloniki “G.Papanikolaou”, Aristotle University of Thessaloniki – THESSALONIKI – Greece  
[2]Respiratory Clinic, General Hospital of Thessaloniki “G.Papanikolaou”, Aristotle University of Thessaloniki – THESSALONIKI – Macedonia, Former Yugoslav Republic of

B43  TREATMENT PATTERNS AND MEDICATION ADHERENCE AND PERSISTENCE AMONG PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN REAL-WORLD DATABASE REPRESENTING A LARGE US HEALTH PLAN  
Janis Pruett*[2], Michael Hull[1], Eleena Koepl[1], Yuen Tsang[2], William Drake[1]


POSTER SESSION

Wednesday, February 28, 2018

RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION

B32

B33

B34

B35

B36

B37
B44 HEMODYNAMIC AND EXERCISE EFFECTS OF DIFFERENT TYPES OF INITIAL ORAL COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION
Andrea Rinaldi*, Massimiliano Palazzini, Enrico Gotti, Fabio Dardi, Alessandra Albinii, Enrico Monti, Elisa Zuffa, Daniele Guarino, Filippo Pasca, Nikita Tanese, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Gallè
University of Bologna, Department of Specialized Diagnostic and Experimental Medicine – DIMES- Bologna/IT – Bologna – Italy

B45 INITIAL CLINICAL RESULTS WITH MACITENTAN IN CONGENITAL HEART DISEASE PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Joaquín Rueda-Soriano*1, Josep Lluís Melero-Ferrer2, Carlos Israel Chamorro-Fernández3, Francisco Buendia-Fuentes4, Ana Osa-Sáez5, Luis Martínez-Dolz6
1Servicio de Cardiología. Hospital Universitari i Politécnic La Fe, Valencia – Valencia – Spain, 2Servicio de Cardiología. Hospital de Manises. – Manises – Spain, 3Servicio de Cardiología. Hospital Virgen de los Lirios. – Alcoi – Spain, 4Servicio de Cardiología. Hospital Arnau de Vilanova. – Valencia – Spain

B46 SAFETY AND EFFICACY OF SUBCUTANEOUS TREPETROSTINAL IN CONGENITAL HEART DISEASE- RELATED PULMONARY ARTERIAL HYPERTENSION
Nika Skoro-Sajer*1, Christian Gerges2, Olga HAJNalka Balint3, Monika Kaldararova4, Iveta Simkova5, Johannes Jakowitz6, Harald Gabriel7, Helmut Baumgartner8, Mario Gerges9, Roela Sadushi-Kolici10, David Celemajer11, Irene Lang12
1Cardiology, Medical University of Vienna – Vienna – Austria, 2György Gottsegen, Hungarian Institute of Cardiology – Budapest – Hungary, 3Department of Cardiology and Angiology, Slovak Medical University and National Institute of Cardiovascular Diseases – Bratislava – Slovakia, 4Division of Adult Congenital and Vascular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, – Münster – Germany, 5Sydney Medical School, University of Sydney, – Sydney – Australia

B47 PARENTERAL USE OF PROSTANOIDS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) IN A TERTIARY REFERRAL UNIVERSITY HOSPITAL
Pulmonary Hypertension Clinic, University of Athens, “Attikon” Hospital – Athens – Greece

B48 THE GOAL OF LONG-TERM OXYGEN THERAPY TO AVOID TISSUE HYPOXIA IN PATIENTS WITH PULMONARY HYPERTENSION
Rika Suda*, Nobuhiro Tanabe, Akira Naito, Rintaro Nishimura, Takayuki Jujo, Toshihiko Sugiuira, Seiichiro Sakao, Koichiro Tatsumi
Department of Respiratory, Graduate School of Medicine, Chiba University – Chiba – Japan

B49 DIVERSITY OF BORDERLINE PULMONARY ARTERIAL PRESSURE ASSOCIATED WITH SYSTEMIC SCLEROSIS: 4 CASE SERIES
Eri Sugawara*1, Masaru Kato1, Ryo Hisada2, Hiroyuki Nakamura1, Fujieda Yuichiro1, Kenji Oki2, Toshiyuki Bohtagaki3, Shinsuke Yasuda3, Hiroshi Ohira3, Ichizo Tsuruno2, Masaharu Nishimura2, Tatsuya Atsumi2
1Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University – Sapporo – Japan, 2First Department of Medicine, Hokkaido University Hospital – Sapporo – Japan

B50 REAL LIFE EXPERIENCE WITH REVEAL RISK SCORE FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Celik Sumer*1, Ahmet Kaya Bilge2, Murat Inanc2, Halim Isseyer2, Gulfer Okumus1
1Istanbul University Medical Faculty Department of Pulmonary Diseases – Istanbul – Turkey, 2Istanbul University Medical Faculty Department of Pulmonary Diseases – Istanbul – Turkey

B51 INFLUENCE OF INITIAL RIOMICUAT MONOTHERAPY AND TRANSITION FROM SILDENAFIL TO RIOMICUAT THERAPY IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION ON RIGHT HEART REMODELING AND RIGHT VENTRICULAR – PULMONARY ARTERIAL COUPLING
Irina Taran*1, Anna Belevskaya4, Marina Saidova5, Tamila Martynyuk1, Irina Chazova1
1Postgraduate student of Department of Pulmonary Hypertension and Heart Diseases, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation, 2Dr. Med. Sci., Prof. Head of Department of Ultrasonic Diagnostic Techniques, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation, 3Dr. Med. Sci., Head of Department of Pulmonary Hypertension and Heart Diseases, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation, 4Physician of Ultrasonic Diagnostic Techniques Laboratory, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation – Moscow – Russian Fe, 5RAS Academician, Prof., Dr. Med. Sci., Director of Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Head of Department of Hypertension, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research...
Wednesday, February 28, 2018

**RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION**

**B52 THE VALUE OF CARDIOPULMONARY EXERCISE TESTING IN ASSESSMENT OF THE SEVERITY OF PULMONARY ARTERIAL HYPERTENSION PATIENTS**

Irina Taran\(^{(1)}\), Zarina Valieva\(^{(2)}\), Tamila Martynyuk\(^{(3)}\), Irina Chazova\(^{(4)}\)

\(^{(1)}\)Postgraduate student of Department of Pulmonary Hypertension and Heart Diseases, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation; \(^{(2)}\)PhD of Department of Pulmonary Hypertension and Heart Diseases, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation, Moscow; \(^{(3)}\)Dr. Med. Sci., Head of Department of Pulmonary Hypertension and Heart Diseases, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation, Moscow; \(^{(4)}\)Professor of Medicine, Department of Pulmonary Hypertension, Scientific Research Institute of Clinical Cardiology of A. L. Myasnikov, Russian Cardiology Res

**B53 ENHANCED GLUCOSE METABOLISM IN THE RIGHT VENTRICULAR WALL PREDICTS A PROGNOSTIC IMPACT IN PATIENTS WITH PULMONARY HYPERTENSION**

Nakamura Tomohisa\(^{(1)}\), Tahara Nobuhiro\(^{(1)}\), Sugiyama Yoichi\(^{(1)}\), Bekki Munehisa\(^{(1)}\), Tahara Atsuko\(^{(1)}\), Honda Akihiro\(^{(1)}\), Kumagai Eita\(^{(1)}\), Igata Sachiyo\(^{(1)}\), Fukumoto Yoshihiro

Department of Internal Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Fukuoka, Japan

**B54 HEMODYNAMIC EFFECTS OF THE ORAL PROSTACYCLIN (IP) RECEPTOR AGONIST RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION (PAH)**

Fernando Torres\(^{(4)}\), Harrison Farber\(^{(5)}\), Arsen D Ristic\(^{(6)}\), Vallerie Mclaughlin\(^{(7)}\), John Adams\(^{(8)}\), Stewart Turner\(^{(9)}\), Preston Klassen\(^{(10)}\), Pilar Escrivan-Subias\(^{(11)}\), Namita Sood\(^{(12)}\), Anne M Keoghi\(^{(13)}\), Lewis Rubin\(^{(14)}\)

\(^{(4)}\)Professor of Medicine and Director of the Pulmonary Hypertension Center, Boston University School of Medicine, Boston; \(^{(5)}\)Professor of Internal Medicine and Cardiology, Belgrade University School of Medicine, Assistant Director; \(^{(6)}\)Department of Cardiology of the Clinical Center of Serbia, Coordinator of the National Registry on Pulmonary Hypertension – Belgrade – Serbia; \(^{(7)}\)Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine, Director of Pulmonary Hypertension Program, University of Michigan – Ann Arbor, MI – United States of America; \(^{(8)}\)Director de Cardiología, Hospital 12 de Octubre – Madrid – Spain; \(^{(9)}\)University of Texas Health Science Center of Houston – Houston, TX – United States of America; \(^{(10)}\)Department of Cardiology, St Vincent’s Hospital – Sydney – Australia; \(^{(11)}\)Eminent Professor of Medicine, University of California, San Diego School of Medicine, La Jolla, CA; Adjunct Professor of Medicine, Columbia University College of Physicians and Surgeons – New York, NY; \(^{(12)}\)Medical Director of Lung Transplantation, Head of Pulmonary Hypertension Program, UT Southwestern Medical Center, Dallas, TX – United States of America

**B55 IS REDUCED SYSTEMIC ARTERIAL STIFFNESS A NOVEL SURROGATE INDEX OF SEVERITY IN PATIENTS WITH GROUP 1 PULMONARY ARTERIAL HYPERTENSION?**

Helen Triantafyllidou\(^{(1)}\), Olympia Apostolopoulou\(^{(2)}\), Benas Dimitris\(^{(3)}\), Leonidas Palaiodimos\(^{(4)}\), Mary Varoudi\(^{(5)}\), George Pavlidis\(^{(6)}\), Anastasia Anthi\(^{(7)}\), Loukianos Ralli\(^{(8)}\), Orfanos Stylianos\(^{(9)}\), Hrilakis Tsagkaris\(^{(10)}\), Ignatios Ikonomidou\(^{(11)}\), Apostolos Armaganidis\(^{(12)}\), John Lekakis\(^{(13)}\)

\(^{(1)}\)2nd Department of Cardiology, Medical School, University of Athens, ATTIKON Hospital – Athens – Greece; \(^{(2)}\)Department of Critical Care, Medical School, University of Athens, ATTIKON Hospital – Athens – Greece

**B56 THE ROLE OF SYSTEMIC ENDOTHELIAL GLYCOCALYX IN PATIENTS WITH GROUP 1 PULMONARY ARTERIAL HYPERTENSION**

Helen Triantafyllidou\(^{(1)}\), Olympia Apostolopoulou\(^{(2)}\), Dimitris Benasi\(^{(3)}\), Leonidas Palaiodimos\(^{(4)}\), Mary Varoudi\(^{(5)}\), George Pavlidis\(^{(6)}\), Dimitris Kostantinos\(^{(7)}\), Ignatios Ikonomidou\(^{(8)}\), Stylianos Orfanos\(^{(9)}\), Iraklis Tsagkaris\(^{(10)}\), Anastasia Anthi\(^{(11)}\), Apostolos Armaganidis\(^{(12)}\), John Lekakis\(^{(13)}\)

\(^{(1)}\)2nd Department of Cardiology, Medical School, University of Athens, ATTIKON Hospital – Athens – Greece; \(^{(2)}\)2nd Department of Critical Care, Medical School, University of Athens, ATTIKON Hospital – Athens – Greece

**B57 RIGHT ATRIUM ENLARGEMENT PREDICTS CLINICALLY SIGNIFICANT SUPRAVENTRICULAR ARRHYTHMIAS IN PULMONARY ARTERIAL HYPERTENSION.**

Marcin Waligóra\(^{(1)}\), Anna Tyrka, Jakub Stepniewski, Wojciech Magon, Piotr Podolec, Grzegorz Kopec

Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College at John Paul II Hospital – Krakow – Poland

**B58 ELECTROCARDIOGRAPHIC CRITERIA OF RIGHT VENTRICULAR HYPERTROPHY REFLECT HEMODYNAMIC IMPROVEMENT IN PULMONARY HYPERTENSION.**

Marcin Waligóra\(^{(1)}\), Anna Tyrka, Jakub Stepniewski, Piotr Podolec, Grzegorz Kopec

Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College at John Paul II Hospital – Krakow – Poland

**B59 STRUCTURAL AND FUNCTIONAL STATUS OF THE SYSTEMIC CIRCULATION ARTERIES IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION WITH DIFFERENT FUNCTIONAL ABILITIES AND ENDPOINTS**

Iryna Zhyvylo\(^{(1)}\), Yevhen Titov, Ganna Radchenko, Yuri Sirenko

National Scientific Centre “Institute of Cardiology named after M.D. Strauzhisko” of AMS of Ukraine – Kyiv – Ukraine
POSTER SESSION

Wednesday, February 28, 2018

RISK STRATIFICATION AND MEDICAL THERAPY OF PULMONARY ARTERIAL HYPERTENSION

B60  Clinical Science - 06 Risk stratification and medical therapy of pulmonary arterial hypertension

Elisa Zuffa*, Fabio Dardi, Nikita Tanese, Massimiliano Palazzini, Enrico Gott, Andrea Rinaldi, Enrico Montì, Alessandra Albini, Daniele Guarino, Filippo Pasca, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Galiè

University of Bologna, Department of Specialized Diagnostic and Experimental Medicine - D MES - Bologna/IT – Bologna – Italy

RIGHT VENTRICULAR ASSISTANCE AND LUNG TRANSPLANTATION

B61  PERCUTANEOUS ATRIAL SEPTOSTOMY WITH PERIPHERAL STENT IN A PATIENT WITH SYNCOPE AND REFRAC TORY PULMONARY ARTERIAL HYPERTENSION AND MILD HYPOXIA

Vasil Velchev*
St. Anna Hospital – Sofia – Bulgaria

TRIALS DESIGN AND NEW THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION

B62  POTENCY, SELECTIVITY, AND COMPARATIVE PLATELET AND VASCULAR ACTIVITY OF RALINEPAG ACTING ON IP RECEPTORS IN HUMAN ISSUES


1William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London – London – United Kingdom, 2Institute of Cardiovascular Science, University College London – London – United Kingdom, 3Arena Pharmaceuticals – San Diego, CA – United States of America

B63  SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS (IPF) AND PULMONARY HYPERTENSION (PH): A PHASE IIIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY


1Department of Internal Medicine V, LMU and Asklepios Fachkliniken Gauting, Comprehensive Pneumology Center – Munich – Germany, 2NOVA Heart and Vascular Institute, Inova Fairfax Hospital – Vienna, VA – United States of America, 3U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS – Milan – Italy, 4Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, University of Leuven – Leuven – Belgium, 5F Hoffmann-La Roche, Ltd. – Basel – Switzerland, 6Interstial Lung Disease Unit, Royal Brompton Hospital – London – United Kingdom
Wednesday, February 28, 2018

POSTER SESSION

TRIALS DESIGN AND NEW THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION

B64 INDIVIDUALIZED HOME-BASED EXERCISE PROGRAM FOR THE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS: MULTIPLE CASE STUDY
Lina Butane*, Daina Šmite, Andris Skride
Latvian – Riga – Latvia

B65 UDENAFIL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
Hyuk Jae Chang*1, Shin-Jeong Song1, Sung-A Chang2, Hyung Kwan Kim3, Duk-Kyung Kim4
1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul – Seoul – Korea, Republic of; 2Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine – Seoul – Korea, Republic of; 3Department of Cardiology, Seoul National University Hospital, Seoul, South Korea – Seoul – Korea, Republic of

B66 ACUTE HEMODYNAMIC CHANGES AFTER SINGLE ADMINISTRATION OF UDENAFIL IN PULMONARY ARTERIAL HYPERTENSION (PHASE IIA STUDY)
Sung-A Chang5,6, Hyung-Kwan Kim7, Hyuk Jae Chang7, Duk-Kyung Kim7
5Seoul National University Hospital – Seoul – Korea, Republic of; 6Yonsei Severance Hospital – Seoul – Korea, Republic of; 7Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine – Seoul – Korea, Republic of

B67 BASELINE AND DEMOGRAPHIC DATA ON THE FIRST 150 PATIENTS FROM SPHERE (UPTRAVI® [SELEXIPAG]: THE USERS DRUG REGISTRY)
Kelly Chin*1, Kristin Highland2, Nick H Kim2, Murali Chakinala2, Anna Hemnes2, Harrison Farber3, Carol Zhao3, Mike Keating3, Brian Hartline3, Johanna Colvin3, Valerie McLaughlin3
1Pulmonary and Critical Care Division, University of Texas Southwestern Medical Center – Dallas – United States of America; 2Cleveland Clinic – Cleveland – United States of America; 3Washington University School of Medicine – St. Louis – United States of America; 4Vanderbilt University Medical Center – Nashville – United States of America; 5Boston University School of Medicine – Boston – United States of America; 6Actelion Pharmaceuticals US – South San Francisco – United States of America; 7Actelion Pharmaceuticals US – South San Francisco – United States of America; 8University of Michigan Medical Center – Ann Arbor – United States of America

B68 ERS TASK FORCE: EXERCISE TRAINING AND REHABILITATION IN PATIENTS WITH SEVERE CHRONIC PULMONARY HYPERTENSION
Ekkehard Grünig*1, Christina Eichstaedt1, Joan-Albert Barberà2, Isabel Blanco2, Eduardo Bossoni3, Antonio Cittadini3, Marion Delcroix4, Sean Gainer5, Stefano Ghio6, Lina Gumbiene6, Frances Handoko De Meij6, Martin Johnson6, David Kielty7, Gabor Kovaci7, Alison MacKenzie7, Robert Naeije8, Silvia Ulrich9, Horst Olschewski10, Abilio Resi10, Márió Santos10, Anton von Noordegraaf10, Andrew Peacock10, Exercise In Ph Research Group10
1Centre for Pulmonary Hypertension, Thoracics Clinic at the University Hospital Heidelberg – Heidelberg – Germany; 2Hospital Clinic at the University of Barcelona – Barcelona – Spain; 3Department of Cardiac Surgery, University Hospital Salerno – Salerno – Italy; 4Department of Pneumology, University Hospital Leuven – Leuven – Belgium; 5Department of Pulmonology, Maastricht University Medical Centre – Maastricht – Netherlands; 6Department of Cardiology, University Hospital Amsterdam – Amsterdam – Netherlands; 7Golden Jubilee Hospital – Glasgow – United Kingdom; 8Department of Cardiology, University Clinic Brussels - Erasme Hospital – Brussels – Belgium; 9Department of Respiratory Medicine, Royal Hallamshire Hospital – Sheffield – United Kingdom; 10Department Internal Medicine, Medical University of Graz – Graz – Austria; 11Centre for Pulmonary Hypertension, University Hospital Zurich – Zurich – Switzerland; 12Department of Internal Medicine, Hospital Geral de Santo António – Porto – Portugal; 13Cardiology and Pneumology – Europe – United Kingdom

B69 ADVANCED CORRECTIVE TREATMENT USING PULMONARY VASOREACTIVITY TESTING IN PATIENTS WITH EISENMENGER SYNDROME WITH CONGENITAL HEART DISEASES; RETROSPECTIVE STUDY IN SINGLE CENTER
Jo Won Jung*, Se Yong Jung, Jae Young Choi, Yu Lim Shin, Han Ki Park, Young Hwan Park
Yonsei University College of Medicine – Seoul – Korea, Republic of

B70 CONTINUOUS S.C. DIURETIC THERAPY AT HOME IMPROVES QUALITY OF LIFE IN END-STAGE PAH
Miriam Kap*
Erasmus MC – Rotterdam – Netherlands

B71 BENEFICIAL EFFECTS OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND IRON DEFICIENCY: A LONG-TERM PILOT STUDY
Tilmann Kramer*, Kristiana Natsina, Thomas Viethen, Felix Gerhardt, Daniel Dumitrescu, Stephan Baldus, Stephan Rosenkranz
Klinik II für Innere Medizin, Herzzentrum der Universität zu Köln, Germany – Köln – Germany
POSTER SESSION

Wednesday, February 28, 2018

TRIALS DESIGN AND NEW THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION

B72 IDENTIFICATION OF CELASTRAMYCIN AS A NOVEL THERAPEUTIC AGENT FOR PULMONARY ARTERIAL HYPERTENSION
Tohoku University – Sendai – Japan

B73 CHRONIC TRANSFUSION EXCHANGES IN THE MANAGEMENT OF SICKLE CELL DISEASE-ASSOCIATED PRECAPILLARY PULMONARY HYPERTENSION: A PILOT STUDY
Turpin Matthieu*, Parent Florence, Jais Xavier, Montani David, Sitbon Olivier, Humbert Marc, Simonneau Gerald, Savale Laurent
Service de pneumologie - CHU Bicêtre – Le Kremlin Bicêtre – France

B74 SAFETY AND EFFICACY OF IMMUNOADSORPTION AS AN ADD-ON TO MEDICAL TREATMENT IN PATIENTS WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (IPAH)
Christian Nagel[2], Benjamin Egenlauf[1], Ralf Ewert[3], Hans Lehmkuhl[4], Stephan Rosenkrantz[1], Nicola Benjamin[1], Vedat Schwenger[3], Felix Herth[1], Ekkehard Grünig[1]
[1]Centre for Pulmonary Hypertension, Thorax Clinic at the University Hospital Heidelberg – Heidelberg – Germany, [2]Clinic for Internal Medicine, Greifswald University Hospital – Greifswald – Germany, [3]Department of Cardiology, Heart Center at the University Hospital Cologne and Cologne Cardiovascular Research Center – Cologne – Germany, [4]Department of Nephrology, Klinikum Stuttgart – Stuttgart – Germany, [5]Department of Internal Medicine, Pulmonology and Critical Care Medicine, Thorax Clinic at the University Hospital Heidelberg – Heidelberg – Germany

B75 PRECLINICAL AND PHASE 1 CLINICAL CHARACTERIZATION OF LIQ861, A NEW DRY POWDER FORMULATION OF TREPROSTINIL
Mike Royal[4], Robert Roscigno[2], Toby Vaughn[1], Stephanie Anderson[1], William Wargin[2], Rex Williams[1], Clint Forsythe[1], Thomas Hunt[1], Patrick Normand[2], Manal Hantash[5], John Dillberger[2]

B76 IDENTIFICATION OF EMETINE AS A NOVEL THERAPEUTIC AGENT FOR PULMONARY HYPERTENSION IN RATS -HIGH-THROUGHPUT SCREENING OF 5,562 COMPOUNDS-
Mohammad Abdul Hai Siddique*, Kimio Satoh, Ryo Kurosawa, Md Elias Al-Mamun, Nobuhiro Kikuchi, Junichi Omura, Taiju Satoh, Masamichi Nogi, Shinichiro Sunamura, Hiroaki Shimokawa
Department of Cardiovascular Medicine – Sendai – Japan

B77 PYRIDOXAMINE ATTENUATED THE SMOOTH MUSCLE CELL PROLIFERATION AND HEMODYNAMIC AGGRAVATION IN THE PULMONARY ARTERY HYPERTENSION ANIMAL MODEL

B78 THE MOTION STUDY: A RESPONDER ANALYSIS OF RIOCIGUAT
Namita Sood[4], Alvaro Aranda[2], David Platt[3], Larose Anneliese[2], Frank Kleinjung[3], Gerald O’brien[3]
POSTER SESSION

Wednesday, February 28, 2018

PH DUE TO LEFT HEART DISEASES

B79 HEMODYNAMIC PREDICTORS OF ACUTE RIGHT HEART FAILURE AFTER HEART TRANSPLANTATION (HT). EMERGING ROLE OF PULMONARY ARTERY COMPLIANCE (PAC)
Oscar Aguierre-Zurita*, David Galvez, Walter Alarco, Oscar Guerrero, Miguel Lescano, Christian Sopliopuco, Ruth Villarroel, Ana Shiuayro
INCOR – LIMA – Peru

B80 PDE-5 INHIBITORS FOR PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE: POTENTIAL BENEFIT?
Hayley Barnes*[1], Zoe Brown*[2], Andrew Burns*[3], Trevor Williams*[3]

B81 CLINICAL PHENOTYPES, VENTILATORY RESPONSES TO EXERCISE AND OUTCOMES OF PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE: ROLE OF THE PRE-CAPILLARY COMPONENT
Sergio Caravita*[1], Andrea Fain*[1], Sandy Caroline D’Arauj*[2], Céline Dewachter*[1], Laura Chomette*[1], Antoine Bondue*[1], Robert Naeije*[2], Gianfranco Parati*[1], Jean-Luc Vachiery*[1]

B82 DYSREGULATION OF WNT-RELATED SIGNALING PATHWAY CORRELATES WITH THE DEVELOPMENT OF PH SECONDARY TO LEFT VENTRICULAR DYSFUNCTION
Zen-Kong Dai*, I-Chen Chen, Jong-Hau Hsu
Dept. of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University – Kaohsiung – Taiwan

B83 A NEW SCORE TO DIFFERENTIATE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION FROM PULMONARY HYPERTENSION DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION
Fabio Dardi*[1], Nikita Tanese*[1], Sergio Caravita*[2], Andrea Rinaldi*[2], Celine Dewachter*[1], Enrico Gott*[1], Thomas Nguyen*[2], Enrico Mont*[1], Alessandra Albin*[1], Massimiliano Pannazzano*[1], Alessandra Manes*[1], Jean Luc Vachiery*[1], Nazzareno Galie*[1]

B84 PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE – A HEMODYNAMIC STUDY
Christian Gerges*[1], Mario Gerges*[1], Pierre Fesle*[2], Anna-Maria Pietr[1], David Cellerier*[1], Irene Lang*[1]
[1] Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna – Vienna – Austria, [2] PhyMedExp, University of Montpellier, INSERM U1045, CNRS UMR 9214, and Department of Internal Medicine, Laparosonie Hospital – Montpellier – France, [3] Division of Cardiology, Ferrarotto Hospital, University of Catania – Catania – Italy, [4] Department of Cardiology, Sydney Medical School, University of Sydney – Sydney – Australia

B85 EFFECTS OF CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION ON PULMONARY HAEMODYNAMICS IN ADVANCED HEART FAILURE PATIENTS
Ada Francesca Giglio*[1], Luciana D’Angelo*[1], Enrico Perna*[1], Enrico Ammirati*[1], Francesca Macera*[1], Manlio Gianni Cipriani*[1], Fabrizio Oliva*[1], Andrea Garascia*[1], Claudio Russo*[2], Maria Frigerio*[1]
[1] 2nd Section of Cardiology-Heart Failure and Transplantation, De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy – Milano – Italy, [2] De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda Ca’ Granda, Milan, Italy – Milano – Italy

B86 GENETIC ANALYSIS AND CHAMBER SPECIFIC GENE EXPRESSION ANALYSIS IN PATIENTS WITH CPC-PH AND IPC-PH
Hidetaka Kikota*, Yoshihiro Asano, Ayako Takuo, Yohei Miyashita, Hiroshi Miyawaki, Tomohito Ohtani, Yoshiki Sawa, Keiko Yamauchi-Takahara, Yasushi Sakata
Osaka University Graduate School of Medicine – Suta – Japan

B87 THERAPEUTIC POTENTIAL OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION AND COMBINED POST- AND PRE-CAPILLARY PULMONARY HYPERTENSTION
Tilmann Kramer*[1], Kristina Orlov*a, Felix Gerhardt*b, Daniel Dumitrescu*b, Henrik Ten Freyhaus*a, Martin Hellmich*a, Stephan Baldus*a, Stephan Rosenkranz*a

B88 PRESENCE OF PULMONARY HYPERTENSION IS A POOR PROGNOSTIC FACTOR IN PATIENTS WITH PRIMARY MITRAL REGURGITATION NOT IN SECONDARY MITRAL REGURGITATION
Ju-Hee Lee*[1], Jae-Hyeong Park*[1], Hee-Jin Kwon*[1], Seok-Woo Seong*[1], Jin Kyung Ohh*[2], Myeong-Chan Cho*[2]
**POSTER SESSION**

**Wednesday, February 28, 2018**

**PH DUE TO LEFT HEART DISEASES**

**B89** FLUID CHALLENGE DURING RIGHT HEART CATHETERIZATION: AN EXPERIENCE FROM A TERTIARY PULMONARY HYPERTENSION REFERRAL CENTRE

Nima Moghaddam[1], John Swistoni[1], Robert D Levy[1], Lisa Lee[2], Victor F Huckell[1], Nathan W Brunner[1]


**B90** EFFECT OF IMPROVEMENT OF PULMONARY HYPERTENSION AND/OR LEFT VENTRICULAR SYSTOLIC FUNCTION ON THE LONG-TERM PROGNOSIS OF PATIENTS WITH PULMONARY HYPERTENSION WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION

Jae-Hyeong Park[1], Ju-Hee Lee[1], Hee-Jin Kwon[1]

[1]Chungbuk National University Hospital – Cheongju – Korea, Republic of

**B91** COMPARATIVE OUTCOME OF INCIDENT PATIENTS WITH PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE ACCORDING WITH THE HAEMODYNAMIC CLASSIFICATION OF THE 2015 ESC-ERS PULMONARY HYPERTENSION GUIDELINES

Filippo Pasca[1], Fabio Dardi, Massimiliano Palazzini, Enrico Gotti, Andrea Rinaldi, Alessandra Albini, Enrico Monti, Elisa Zuffa, Daniele Guarino, Nikita Tanese, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Galiè

University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT – Bologna – Italy

**B92** NEDA PH-LHD PREDICTIVE MODEL: VALIDATION OF DIASTOLIC MARKERS OF PULMONARY HYPERTENSION WITH RIGHT HEART CATHETERISATION

Geoff Strange[1], David Playford[1], Pyi Naing[1], Jim Codde[1], David Celemajer[1], Gregory Scalia[1], Kevin Chung[1]


**B93** RHO-KINASE AND CYCLOPHILIN A AS NOVEL THERAPEUTIC TARGETS FOR CARDIAC DIASTOLIC DYSFUNCTION AND POST-CAPILLARY PULMONARY HYPERTENSION


Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine – Sendai – Japan

**B94** MEAN VELOCITY OF THE PULMONARY ARTERY AS AN EARLY PROGNOSTIC INDICATOR IN HFREF IN RELATION WITH FIBROSIS BIOMARKERS GALECTIN-3 AND ST2/LI-1.

Blanca Trejo-Velasco[1], Oscar Fabregat-Andrés[1], Maria Pilar García-González[1], Monica Ferrando[1], Diana Perdomo-Londoño[1], Joaquina Belchí[1], Cristina Albiach-Montañana[1], Sergio Sánchez-Alvarez[1], Juan Pablo Cardenas-Tealido[1], Salvador Morell-Cabedo[1], Francisco Ridocci-Soriano[1]


**B95** A RARE AND RAPIDLY PROGRESSING CASE OF PULMONARY HYPERTENSION

Yalin Tolga Yaylali*, Sonmez Gokhan

Pamukkale University – Denizli – Turkey
Thursday, March 1, 2018

PH DUE TO CHRONIC LUNG DISEASES

**C10**  A POTENTIAL ROLE FOR PDE-5 INHIBITORS FOR PULMONARY HYPERTENSION DUE TO LUNG DISEASE/HYPOXIA
Hayley Barnes*, Zoe Brown†, Andrew Burns‡, Trevor Williams§
† Alfred Hospital – Melbourne – Australia, ‡Royal Adelaide Hospital – Adelaide – Australia, §Department of Cardiology, St Vincent’s Hospital – Melbourne – Australia

**C11**  SEVERE PULMONARY HYPERTENSION IN TOBACCO-INDUCED RESPIRATORY DISEASES
Samy Chelabi*, Guillaume Chassagnori†, Laurent Savale‡, Jason Weatherald§, Xavier Jasi¶, Athenais Boucry#, Herve Mal$, Pierre-Regis Burgel||, Gerald Simonneau*, Olivier Sitbon†, Marc Humbert§

**C12**  COMPARATIVE OUTCOME OF INCIDENT PATIENTS WITH PULMONARY HYPERTENSION DUE TO LUNG DISEASE ACCORDING WITH THE HAEMODYNAMIC CLASSIFICATION OF THE 2015 ESC-ERS PULMONARY HYPERTENSION GUIDELINES
Daniele Guarino*, Massimiliano Palazzini, Enrico Gotti, Andrea Rinaldi, Fabio Dardi, Alessandra Albini, Enrico Monti, Elisa Zuffa, Filippo Pasca, Nikita Tanese, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Galì
*University of Bologna, Department of Specialized Diagnostic and Experimental Medicine - DIMES - Bologna/IT – Bologna – Italy

**C13**  INHALED ILOPROST AS POTENTIAL NEW TREATMENT FOR GROUP 3 PULMONARY HYPERTENSION
Chih-Hsin Hsu*, Po-Lan Su
*Department of Internal Medicine, National Cheng Kung University Hospital – Tainan – Taiwan

**C14**  PROGNOSTIC FACTORS OF PULMONARY HYPERTENSION WITH SEVERE LUNG DISEASE IN RETROSPECTIVE STUDY
Nakayama Kazuhiko*, Emoto Noriaki, Tamada Naoki, Shinkura Yuto, Onishi Hiroyuki, Yanaka Konichi, Matsuoka Yoichiro, Shinke Yoshiro, Hirata Ken-Ichi
Kobe University Graduate School of Medicine – Kobe – Japan

**C15**  ESTABLISHMENT OF A NOVEL MODEL OF GROUP 3 PULMONARY HYPERTENSION INDUCED BY SU5416/HYPOXIA IN RATS
Yosuke Wada*, Kitaguchi Yoshiaki, Yasuo Masanori, Hanaoka Masayuki
First Department of Internal Medicine, Shinshu University School of Medicine – Matsumoto – Japan

**C16**  A RARE RESPIRATORY CONDITION ASSOCIATED WITH PULMONARY HYPERTENSION
Yalin Tolga Yaylali*, Sinan Durmus, Alperen Emre Akgun, Fatma Evyapan
Pamukkale University – Denizli – Turkey

**C17**  BALLOON PULMONARY ANGIOPLASTY (BPA) AS AN ADDITIONAL TREATMENT OPTION FOR PATIENTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) TREATED WITH RIOCIUGAT.
Shiro Adachi*, Nakano Yoshishisa†, Tajima Fumitaka‡, Shimokata Shigetake§, Kamimura Yoshihiro¶, Okumura Naoki¶, Murohra Yooioki¶, Kondo Takahisa#
*Nagoya university graduate school of medicine – nagoya – Japan, †Nagoya university hospital – Nagoya – Japan

**C18**  SUBMASSIVE PULMONARY EMBOLISM TREATMENT WITH ULTRASOUND-ACCELERATED THROMBOLYSIS (SPEAR) TRIAL: A PROSPECTIVE STUDY.
Wael Berjaoui*, Michael Knox, Reda Girgis, David Langholz
Spectrum Health – Grand Rapids – United States of America

**C19**  PREVALENCE AND LONG TERM OUTCOME OF CTEPH - SINGLE CENTRE EXPERIENCE.
Marcela Bohacekova*, Tatiana Valkovicova, Monika Kaldararova, Iveta Simkova
Department of Cardiology and Angiology, Medical Faculty, Slovak Medical University and National Institute of Cardiovascular Diseases, – Bratislava – Slovakia
C20  IS SUBDURAL HAE-MORRHAGE AFTER PULMONARY ENDARTERECTOMY UNDER-ESTIMATED?
Alicia Xue Fen Chia1, Jonathan Yap2, Wen Ruari1, Kenny Wei-Tsen Loh3, Foong Koon Cheah3, Ai Leen Ang2, Ghee Chee Phua3, Dui Wen Sewa3, Ju Le Tan1, David Jenkins1, Victor Tar Toong Chao1, Soo Teik Lim1

C21  ABSENCE OF THE FACTOR V LEIDEN MUTATION AND GENETIC RISK FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Mark Dodson1, Kelli Sumner1, Jadyd Sanders1, Lynette Brown2, Scott Stevens2, Scott Woller2, Hunter Best2, Gregory Elliott2
1ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories – Salt Lake City, UT – United States of America, 2Department of Medicine, Intermountain Medical Center – Murray, UT – United States of America

C22  EFFECT OF BALLOON PULMONARY ANGIOPLASTY ON RIGHT VENTRICULAR AFTERLOAD IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Christian Gerges1, Mario Gerges1, Nika Skoro-Sajer3, Roela Saduschi-Koli1, Bernhard Moser1, Shahrokh Taghavi1, Walter Klepetko1, Hiromi Matsubara3, Irene Lang1
1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, General Hospital – Vienna – Austria, 2Department of Surgery, Division of Thoracic Surgery, Medical University of Vienna, Vienna General Hospital – Vienna – Austria, 3Department of Cardiology, Okayama Medical Center – Okayama – Japan

C23  VENTILATION/PERFUSION SCINTIGRAPHY FOR THE DIAGNOSIS OF CTEPH AFTER SPLENECTOMY
Mario Gerges1, Christian Gerges1, Karanikas Georgios1, Wolfgang Birkfellner1, Isolde Maria Weinberg1, Ilse Schwarzinger2, Max Publig3, Nika Skoro-Sajer1, Maria Frey1, Michael Schaaffrich1, Johannes Jakowitsch1, Klaus Lechner1, Bernhard Moser1, Taghavi Sharokh1, Walter Klepetko1, Marcus Hacker1, Irene Marthe Lang1
1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, General Hospital Vienna (AKH-Wien), Medical University of Vienna – Vienna – Austria, 2Center for Medical Physics and Biomedical Engineering, Vienna General Hospital Vienna (AKH-Wien), Medical University of Vienna – Vienna – Austria, 3Department of Laboratory Medicine, Division of Medical-Chemical Laboratory Diagnostics, General Hospital Vienna (AKH-Wien), Medical University of Vienna – Vienna – Austria, 4Department of Internal Medicine II, Division of Cardiology, General Hospital Vienna (AKH-Wien), Medical University of Vienna – Vienna – Austria, 5Department of Cardiology, Division of Thoracic Surgery, General Hospital Vienna (AKH-Wien), Medical University of Vienna – Vienna – Austria

C24  EXPERIENCE OF ONE YEAR OF BALLOON PULMONARY ANGIOPLASTY IN A SINGLE CENTER: SAFETY AND SHORT TERM RESULTS
Enrico Gott1, Massimiliano Palazzini, Andrea Rinaldi, Fabio Dardi, Enrico Monti, Alessandra Albini, Elisa Zuffa, Daniele Guarino, Filippo Pasca, Vittoria Tane, Mariangela Rotunno, Antonio Colangelo, Alessandra Manes, Nazzareno Galli
University of Bologna, Department of Specialized Diagnostic and Experimental Medicine – DIMES - Bologna/IT – Bologna – Italy

C25  EXERCISE RIGHT HEART CATHETERIZATION IN PATIENTS WITH CHRONIC THROMBOEMBOLIC DISEASE – THERE IS A NEED FOR DEFINITION OF EXERCISE PULMONARY HYPERTENSION
Stefan Guth1, Christoph Wiedenroth1, Rieth Andreas1, Christoph Liebetrau1, Manuel Richter1, Hossein Ardeschir Ghofrani2, Eckhard Mayer2
1Kerckhoff-Clinic – Bad Nauheim – Germany, 2University Clinic Giessen – Giessen – Germany

C26  END-STAGE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: UNIQUE MOLECULAR AND HISTOPATHOLOGICAL IMPRINT
Dijana Iloska1, Jochen Wilhelm2, Stefan Guth3, Rajkumar Sava1, Ralph Schermuly2, Ludger Fink3, Werner Seege1, Eckhard Mayer2, Soni Pullarnseti Sava1
1Max-Planck-Institute for Heart and Lung Research – Bad Nauheim – Germany, 2Department of Internal Medicine, Universities of Giessen and Marburg Lung Center – Giessen – Germany, 3Kerckhoff-Klinik – Bad Nauheim – Germany

C27  USEFULNESS OF PERCUTANEOUS TRANSLUMINAL PULMONARY ANGIOPLASTY FOR CHRONIC PULMONARY THROMBOEMBOLIC DISEASE
Takumi Inami1, Masaharu Kataoka1, Yohei Shigeta1, Kaori Takeuchi1, Hanako Kikuchi1, Ayumi Goda1, Haruhisa Ishiguro1, Hideaki Yoshino1, Toru Satoh1
1Kyoto University School of Medicine – Tokyo – Japan, 2Keio University School of Medicine – Tokyo – Japan

C28  THE RELATIONSHIP BETWEEN THE DIAMETER OF BRONCHIAL ARTERIES AND THE RISK OF PULMONARY EDEMA OR AIRWAY BLEEDING FOR PULMONARY ENDARTERECTOMY
Takayuki Jujo*, Tanabe Nobuhiro, Sakao Seichiro, Akira Naito, Suda Rika, Kasai Hajime, Nishimura Rintaro, Sugaiura Yoshikio, Ishida Keiichi, Tatsumi Koichiro
Graduated School of Medicine, Chiba University – Chiba – Japan

Thursday, March 1, 2018
POSTER SESSION
Thursday, March 1, 2018

C29  HOW DIFFERENT IS CENTRAL VERSUS PERIPHERAL CTEPH?
Monika Kaldararova[1], Marcela Bohacekova[1], Jozef Pacak[1], Tatiana Valkovicova[2], Anna Remkova[2], Pavel Jansa[2], Jaroslav Lindner[2], Iveta Simkova[2]
[1]Department of Cardiology and Angiology, Slovak Medical University and National Institute of Cardiovascular Diseases – Bratislava – Slovakia, [2]Department of Internal Medicine, Slovak Medical University – Bratislava – Slovakia, [3]Center for Pulmonary Hypertension, General Teaching Hospital and 1st Faculty of Medicine of Charles University – Prague – Czech Republic, [4]2nd Surgical Department-Department of Cardiovascular Surgery, General University Hospital and the First Faculty of Medicine, Charles University – Prague – Czech Republic

C30  CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN FIRSTLY DIAGNOSED PULMONARY EMBOLISM: INCIDENCE, PREDICTORS, AND PROGNOSTIC IMPLICATIONS
Kye Hun Kim*, Hyukjin Park, Jae Yeong Cho, Hyun Ju Yoon, Jong Chun Park
Chonnam National University Hospital – Gwangju – Korea, Republic of

C31  FEASIBILITY AND SAFETY OF SHORTENING HOSPITAL STAY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION TREATED WITH BALLOON PULMONARY ANGIOPLASTY
Mai Kimura*, Takashi Kohno, Takashi Kawakami, Masaharu Kataoka, Toshimitsu Tsugui, Sarasas Isobe, Shinsuke Yuasa, Yui Itabashi, Mitsushige Murata, Keiichi Fukuda
Department of Cardiology, Keio University School of Medicine – Tokyo – Japan

C32  EVALUATION OF HEMODYNAMIC RESPONSES TO EXERCISE IN PATIENTS WITH CTEPH AFTER BALLOON PULMONARY ANGIOPLASTY
Sugimura Koichiro*, Aoki Tatsu, Tatebe Shunsuke, Yamamoto Saori, Yoaota Nobuhiro, Sato Haruka, Kozu Katsuya, Konno Ryo, Shimokawa Hiroaki
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine – Sendai – Japan

C33  CHANGES IN VESSEL DIAMETER AND LOCAL ELASTIC PROPERTIES OF PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY.
Wojciech Magon*, Jakub Stepniewski, Marcin Waligora, Kamil Jonas, Piotr Podolec, Grzegorz Kopec
Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College at John Paul II Hospital – Krakow – Poland

C34  3D PRINTING IN PATIENTS WITH PULMONARY HYPERTENSION
Athanassios Manginas[1]*, Georgios Bobas[2]

C35  DRUG-DRUG INTERACTION EVALUATION BETWEEN DIRECT ORAL ANTICOAGULANTS AND PHOSPHODIESTERASE-5 INHIBITORS: A POTENTIAL RISK FOR PULMONARY HYPERTENSION PATIENTS?
Victor Margelidon-Cozzolino[1]*, Sophie Hodin[2], Xavier Delavenne[2], Laurent Bertoletti[3]

C36  PULMONARY ENDARTERECTOMY: BOLOGNA UNIVERSITY EXPERIENCE
Sofia Martin-Suarez[1]*, Gregorio Gliozzi[2], Nazzaren Galiè[2], Davide Pacini[2]

C37  MULTI-STEP THERAPY WITH RIOCIUGAT, BALLOON PULMONARY ANGIOPLASTY, AND CARDIAC REHABILITATION FOR INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Takeshi Ogo*, Shigefumi Fukui, Yoichi Goto, Nao Konagai, Ryotaro Asano, Jin Ueda, Akihiro Tsuji, Yoshiaki Morita, Michio Nakanishi, Keichi Fukuda, Satoshi Yasuda, Michio Nakanishi
National Cerebral and Cardiovascular Centre – Osaka – Japan

C38  RESIDUAL RIGHT VENTRICULAR REMODELING FOLLOWING BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Takeshi Ogo[1]*, Ryotaro Asano[2], Ohta-Ogo Keiko[3], Shigefumi Fukui[1], Akihiro Tsuji[1], Jin Ueda[1], Nao Konagai[3], Keichi Fukuda[2], Yoshiaki Morita[2], Satoshi Yasuda[3]

C39  CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC SYNTHETIC CANNABINOIDS ‘BONZAI’ USE
Gül Öngen[1]*, Ersan Atahani[2], Burçak Kılıçkiran Avc[2], Bedrettin Yıldızel[2]
C40 PULMONARY BLOOD VOLUME BY DUAL-ENERGY CT IS A NEW MANAGEMENT INDEX FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Hiroyuki Onishi*, Nakayama Kuzuhiko†, Yanaka Kenichi†, Tamada Naoki†, Izawa Yu†, Shinikura Yuto†, Tuboi Yasunori†, Shimoyama Shinsuke†, Nishii Tatsuya†, Kono Atushi†, Negi Noriyuki†, Mori Shumei†, Otake Hiromasa†, Satomi-Kobayashi Seimi†, Shinke Toshiro†, Emoto Noriaki†, Hirata Ken-ichi†
†Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine – Kobe – Japan, †Division of Radiology, Center for Radiology and Radiation Oncology, Kobe University Hospital – Kobe – Japan, †Department of Radiology, Kobe University Graduate School of Medicine – Kobe – Japan, †Department of Clinical Pharmacy, Kobe Pharmaceutical University – Kobe – Japan

C41 REPEATED EMBOLIZATION COMBINED WITH INHIBITION OF ANGIogenesis RESULTS IN EARLY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RABBITS
Rozenn Quarck†, Allard Wagenaar†, Birger Tielemans†, Frédéric Perroz†, Peter Dorfmüller†, Catharina Belge†, Marion Delcroix†
†KU Leuven – Leuven – Belgium, †University Hospitals Leuven – Leuven – Belgium, †University Paris Sud – Le Plessis Robinson – France

C42 PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION FROM A SINGLE SINGAPORE CENTRE
Wen Ruan†, Kevin Quah†, Jonathan Yap†, Aidila Binte Ismaill†, Doo Wen Sew‖, Ghee Chee Phua‖, Ai Leen Ang‖, Foong Koon Cheah‖, Kenny Loh‖, Chia Alicia Xue Feni‖, Choong Hee Lim‖, Jenkins David‖, Victor Tat Toong Chao‖, Soo Teik Lim‖, Lu Le Tan‖
‖National Heart Centre Singapore – Singapore – Singapore, ‖Singapore General Hospital – Singapore – Singapore, ‡Papworth Hospital NHS trust – London – United Kingdom

C43 SUBCUTANEOUS TREPSTOPSTINIL FOR THE TREATMENT OF NON-OPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A RANDOMIZED, CONTROLLED TRIAL (CTEPH)
Roela Sadushi-Kolic*, Pavel Jansai*, Grzegorz Kopeć†, Adam Torblicki†, Ioana-Alexandra Campean†, Gert Hoeffken†, Nika Skoro-Sajer†, Jelena Banjic†, Kristof Karlocai†, Regina Steringer-Mascherbauer†, Miroslav Samzarjić†, Barbara Salobir†, Walter Klepetko†, Irene Marthe Lang†
†Charles University of Prague, Cardiology – Prague – Czech Republic, ‡Department of Cardiac and Vascular Diseases Jagiellonian University Medical College Centre for Rare Cardiovascular Diseases John Paul II Hospital – Krakow – Poland, ††John Paul II Hospital, Cardiac and Vascular Diseases Centre for Rare Cardiovascular Diseases – Warsaw – Poland, †††Medical University of Vienna, Internal Medicine II, Cardiology – Vienna – Austria, ††††Internal Medicine I, Pulmonary Disease, University Carl Gustav Carus – Dresden – Germany, †‡Slovak Medical University, Cardiology – Bratislava – Slovakia, †‡‡Semmelweis University Heart Center, Cardiology – Budapest – Hungary, †‡‡‡Elisabethinen University Teaching Hospital, Cardiology – Linz – Austria, †‡‡‡‡University Hospital Centre Zagreb, Respiratory Diseases – Zagreb – Croatia, †††University Medical Centre of Ljubljana, Internal Medicine, Pulmonary Diseases and Allergy – Ljubljana – Slovenia, ††††Medical University of Vienna, Thoracic Surgery – Vienna, Austria, †††††University Hospital Centre Dresden – Dresden – Germany, †‡‡‡Slovak Medical University, Cardiology – Bratislava – Slovakia, †‡§Charles University of Prague, Cardiology – Prague – Czech Republic

C44 THE ESC/ERS RISK ASSESSMENT INSTRUMENT FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IS ALSO APPLICABLE IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Anna Sandqvist†, David Kyllhammar†, Barbro Kjellström†, Stefan Söderberg†
†Department of Pharmacology and Clinical Neuroscience, Clinical Pharmacology, Umeå University – Umeå – Sweden, †Department of Clinical Physiology and Department of Medicine and Health Sciences, Linköping University – Linköping – Sweden, †Department of Medicine, Cardiology Unit, Karolinska Institute – Stockholm – Sweden, †Department of Public Health and Clinical Medicine, Heart Centre, Umeå University – Umeå – Sweden

C45 A TREATMENT GOAL TO IMPROVE RENAL FUNCTION AFTER BALLOON PULMONARY ANGIOPLASTY IS REDUCING PULMONARY VASCULAR RESISTANCE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Isobe Saras*, Ikabashi Yuji, Kawakami Takeshi, Kataoka Masaharu, Murata Mitsuhide, Fukuda Keiichi
Keio university – Tokyo – Japan
POSTER SESSION

Thursday, March 1, 2018

CTEPH

C46  EARLY OUTCOMES FOLLOWING PULMONARY ENDARTERECTOMY: AN AUSTRALIAN TERTIARY REFERRAL CENTRE EXPERIENCE
Sarah Scheuer[1], Sam Emmanuel[1], Anne Keaghi[2], Joanna Pepeke-Zaba[2], David Jenkins[3], David Boshell[1], Eugene Kotylar[4], Kumud Dhital[2]

C47  PREDICTORS FOR WORSENING HEMODYNAMICS DURING FOLLOW-UP PERIOD AFTER BALLOON PULMONARY ANGIOPLASTY
Yuto Shinkura[1], Kazuhiko Nakayama[2], Hiroyuki Onishi[1], Naoki Tamada[2], Yasunori Tsuibo[2], Hiromasa Otake[2], Seimi Satomi-Kobayashi[3], Toshiro Shinke[2], Noriaki Emoto[3], Ken-Ichi Hirata[2]
[1]Department of Clinical Pharmacy, Kobe Pharmaceutical University, Japan – Kobe – Japan, [2]Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine – Kobe – Japan, [3]Clinical Pharmacy, Kobe Pharmaceutical University – Kobe – Japan

C48  A SIMPLE PREDICTIVE ALGORITHM FOR MORTALITY RISK IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Nika Skoro-Sajer[1], Christian Gerges[1], Mario Gerges[1], Adelheid Panzenböck[1], Johannes Jakowitsch[1], Walter Klepetko[2], David Celemajer[3], Irene Lang[1]

C49  CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION MIMICS PULMONARY EMBOLISM
Andris Skride*, Dana Kigitovica, Valdis Gibietis, Barbara Vitola, Sintija Strautmane
Dr – Riga – Latvia

C50  SAFETY AND EFFICACY OF DIRECT ORAL ANTICOAGULANTS FOR PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN ONE EXPERT CENTER IN JAPAN
Rika Suda*, Nobuhiro Tanabe, Takayuki Jujo, Akira Naito, Rintaro Nishimura, Toshihiko Sugiuara, Seiichiro Sakaoo, Koichiro Tatsumi
Department of Respiratory, Graduate School of Medicine, Chiba University – Chiba – Japan

C51  PULMONARY ENDARTERECTOMY AND BALLOON PULMONARY ANGIOPLASTY SIMILARLY IMPROVE HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.
Naoki Tamada*[1], Kazuhiko Nakayama[1], Ken-Ichi Yanaka[1], Hiroyuki Onishi[1], Yuto Shinkura[2], Kazuhiro P Iwasa[2], Toshiro Shinke[1], Noriaki Emoto[3], Ken-Ichi Hirata[2]
[1]Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine – Kobe – Japan, [2]Graduate School of Health Sciences, Kobe University – Kobe – Japan, [3]Clinical Pharmacy, Kobe Pharmaceutical University – Kobe – Japan

C52  POOR SUBPLEURAL PERFUSION RELATING TO LESS DEVELOPED BRONCHIAL ARTERIES PREDICTS FAILURE AFTER BALLOON PULMONARY ANGIOPLASTY FOR NON-OPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Yu Taniguchi*[1], Philippe Brenot[1], Xavier Jais[1], Carlos Garcia[2], Olivier Planche[2], Elie Fadel[1], Marc Humbert[2], Gerald Simonneau[2]

C53  THE WALL SHEAR STRESS OF THE PULMONARY ARTERIES IN THE PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION BEFORE AND AFTER BALLOON PULMONARY ANGIOPLASTY; ANALYSIS USING COMPUTATIONAL FLUID DYNAMICS.
Hideo Tsubata*[1], Nakanishi Naohiko[1], Itatani Keiichi[2], Fukai Kuniyoshi[1], Yaku Hitoshi[1], Matoba Satoko[1]

C54  HYDATID EMBOLIZATION RELATED CHRONIC PULMONARY HYPERTENSION
Omac Tufekcioglu*[1], Idris Yakut*[1], Yucel Kanaan[2], Ilke Erbay[1], Funda Dereagzi[1], Yesim Akin[1], Levent Birincioglu[1], Hatice Sasmaz[1]
[1]Turkey Yuksek Ihtisas Hospital, Cardiology – Ankara – Turkey, [2]Turkey Yuksek Ihtisas Hospital, Cardiovascular Surgery – Ankara – Turkey
POSTER SESSION

Thursday, March 1, 2018

CTEPH

C55 CASE SERIES OF SEVEN WOMEN WITH UTERINE FIBROIDS LEADING TO THROMBOEMBOLIC DISEASE AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Anjali Vaidya*, Anne-Sophie Lacharite-Roberge, Farhan Raza, Riyaz Bashir, Chandra Dass, Yoshiya Toyoda, Paul Forfia
Temple University Hospital Department of Medicine – Philadelphia – United States of America, Temple University Hospital Heart and Vascular Institute – Philadelphia – United States of America, Temple University Hospital Department of Cardiovascular Surgery – Philadelphia – United States of America, Temple University Hospital Department of Radiology – Philadelphia – United States of America

C56 INITIAL CLINICAL AND HEMODYNAMIC RESULTS OF A REGIONAL PULMONARY THROMBOENDARTERECTOMY PROGRAM
Anjali Vaidya*, Farhan Raza, Anne-Sophie Lacharite-Roberge, Chandra Dass, Riyaz Bashir, Yoshiya Toyoda, Paul Forfia
Temple Heart and Vascular Institute – Philadelphia – United States of America

PEDIATRIC PH

C60 PULMONARY ARTERY HYPERTENSION IS ASSOCIATED WITH DECREASED CARDIAC OUTPUT IN FONTAN PATIENTS
Vincent Aluquin*, Athira Nair, William Lee
Penn State Hershey Children’s Hospital – Hershey, Pennsylvania – United States of America, UCSF Fresno – Fresno, California – United States of America, Penn State University – State College, PA – United States of America

C61 INTRAVENOUS TREPRETSTINIL AND OCCULT FRACTURES IN INFANTS: MORE THAN A CASUAL CORRELATION?
Meghan Bernier*, Lewis Romer
Johns Hopkins School of Medicine – Baltimore – United States of America

C62 THE CARDIOPULMONARY EXERCISE TESTING IN CHILDREN AND ADOLESCENTS WITH PULMONARY ARTERIAL HYPERTENSION.
Mariana Cazalas*, Ines Abella, Alejandro Tocci, Claudio Moros, Maria Sicurello, Haydee Vazquez, Maria Grippo
Argentine Society of Cardiology – Buenos Aires – Argentina

C63 PEDIATRIC PULMONARY HYPERTENSION AT CHILDREN HOSPITAL “DR RICARDO GUTIERREZ” BUENOS AIRES, ARGENTINA
Mariana Elisa Cazalas*, Maria Grippo, Ines Abella, Haydee Vazquez, Maria Sicurello, Alejandro Goldsman, Angela Sardella, Isabel Torres
Argentine Society of Cardiology – Buenos Aires – Argentina

C64 PEDIATRIC PULMONARY HYPERTENSION AND CONGENITAL HEART DISEASE. EXPERIENCE AT CHILDREN HOSPITAL “DR. RICARDO GUTIERREZ” BUENOS AIRES, ARGENTINA.
Mariana Elisa Cazalas*, Maria Grippo, Haydee Vazquez, Alejandro Goldsman, Maria Sicurello, Alberto Quilindro, Angela Sardella, Ines Abella
Children Hospital Dr Ricardo Gutierrez . Buenos Aires. Argentina – Buenos Aires – Argentina
Thursday, March 1, 2018

PEDIATRIC PH

C65 OUTCOMES OF TREATMENTS OF SELECTIVE PULMONARY VASODILATORS AFTER THE TRANSCATHETER CLOSURE IN ATRIAL SEPTAL DEFECT WITH PULMONARY ARTERIAL HYPERTENSION

Jae Young Choi*, Kim Jung Yoon, Kim Ah Young, Jung Jo Won, Jung Se Yong
Division of Pediatric Cardiology, Congenital Heart Disease Center, Severance Cardiovascular Hospital, Department of Pediatrics, Yonsei University College of Medicine, Seoul – Seoul – Korea, Republic of

C66 COMPARISON BETWEEN PAEDIATRIC AND ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Fabio Dardi*, Alessandra Manes, Massimiliano Palazzini, Elisa Zuffa, Enrico Gotti, Andrea Rinaldi, Alessandra Albini, Enrico Monti, Daniele Guarino, Filippo Pasca, Nikita Tanese, Antonio Colangelo, Mariangela Rotunno, Andrea Doni, Nazzareno Galliè
University of Bologna, Department of Specialized Diagnostic and Experimental Medicine – DIME – Bologna/IT – Bologna – Italy

C67 ATRIAL SEPTAL DEFECT FENESTRATED DEVICES IN CHILDREN WITH SEVERE PULMONARY HYPERTENSION

Anne Fournier*, Francisco Gonzales-Barlatay, Maire-Josee Raboisson, Julie Briere, Nagib Dahdah
CHU mere-enfant Sainte-Justine – Montreal – Canada

C68 EPIDEMIOLOGICAL CHARACTERISTICS OF PULMONARY ARTERIAL HYPERTENSION IN THE PEDIATRIC POPULATION. REGISTRATION OF A MEXICAN NATIONAL CENTER.

Humberto Garcia*, Emilia Covian, Sandra Patricia Antunez, Eduardo Melendez, Ramon Flores, Antonio Salgado
ISSSTE – Mexico – Mexico

C69 ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF A PEDIATRIC PULMONARY HYPERTENSION PROGRAM IN MEXICO.

Humberto Garcia*, Silvia Guzman[2], Enrique Gomez Alvarez[2], Maria Emilia Covian[2], Araceli Oliavere[2], Herman Soto[2]
1ISSSTE – Mexico – Mexico, 2HS – Mexico – Mexico, 3ISS – Mexico – Mexico

C70 VENTRICULAR ARTERIAL COUPLING RATIO AND VOLUMES CORRELATE WITH RIGHT VENTRICULAR STRAIN AND PREDICTS OUTCOMES USING THREE-DIMENSIONAL ECHOCARDIOGRAPHY IN PEDIATRIC PULMONARY HYPERTENSION

Pei-Ni Jone*, Michal Schäfer, D Dunbar Ivy
Children’s Hospital Colorado, University of Colorado School of Medicine – Aurora – United States of America

C71 COMPARATIVE ANALYSIS OF DETERMINING RISK FACTORS OF PNEUMOTHORAX COMPLICATING PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN IN THAI NEONATES

Narongsak Nakwan*, Sutthikit Jaroenari, Wuttichart Kamolvisit
Department of Pediatrics, Hat Yai Hospital – Songkhla – Thailand

C72 A CASE OF ATRIAL SEPTAL DEFECT ASSOCIATED PULMONARY ARTERIAL HYPERTENSION RELATED TO EISENMENGER’S SYNDROME

Hidemi Sorimachi*, Noriaki Takama, Masahiko Kurabayashi
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine – Maebashi – Japan

C73 FIRST-IN-CHILD USE OF THE SOLUBLE GUANYLATE CYCLASE STIMULATOR RIOCIGUAT IN PULMONARY ARTERIAL HYPERTENSION

Till Spreemann*, Christoph Happel, Harald Bertram, Georg Hansmann
Hannover Medical School – Hannover – Germany

C74 IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION IN PEDIATRICS: VALIDITY OF DOPPLER COLOR ECHOCARDIOGRAM FOR THE NON-INVASIVE DIAGNOSIS

Carolina Stepphen*, Adelia Marques, Julieta Rancati, Ines Martinez, Jesus Damsky Barbosa
hospital elizalde – buenos aires – Argentina

C75 CONGENITAL HEART DEFECT WITH PULMONARY HYPERTENSION: IS POSSIBLE A SURGICAL CORRECTION AFTER TREATMENT WITH SILDENAFIL?

Carolina Stepphen*, Maria Adelia Marques, Ines Martinez, Ana De Dios, Jesus Damsky Barbosa
hospital elizalde – buenos aires – Argentina
POSTER SESSION

Thursday, March 1, 2018

PATIENTS’ PERSPECTIVES

C76 PHARMACOECONOMIC BURDEN OF PULMONARY HYPERTENSION IN DIFFERENT HEALTH CARE SYSTEMS
Burger Charles D*, Mohamedanwar Ghandour, Divya Padmanabhan Menon
Mayo Clinic – Jacksonville, Florida – United States of America

C77 INTERNATIONAL ENVIRONMENTAL SCAN OF SPECIALIZED PULMONARY HYPERTENSION CLINICS
Carolyn Doyle-Cox*, Gail Nicholson[1], Wendy Gin-Sing[2], Traci Stewart[3]

C78 ORAL UPFRONT COMBINATION THERAPY IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: FROM A RETROSPECTIVE COHORT STUDY
Kentaro Ejiri*, Satoshi Akagi, Toshihiro Sarashina, Kazufumi Nakamura, Hiroshi Ito
Okayama University – Okayama – Japan

C79 ASSESSMENTO OF LUNG ULTRASONOGRAPHY AS PREDICTOR OF PULMONARY INVOLVEMENT IN A COHORT OF PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS COMPPLICATED BY EITHER INTERSTITIAL LUNG DISEASE OR PULMONARY ARTERIAL HYPERTENSION
Elisa Tinazzi*, Federico Confente, Gloria Tacchella, Giuseppe Patuzzo, Claudio Lunardi
University of Verona – Verona – Italy
GENERAL INFORMATION

CONGRESS LOCATION
Nice Acropolis Congress Center
Entrance for the public from Risso Boulevard, Nice
Ph: +33 (0)4 93 92 83 00
Fax: +33 (0)4 93 92 82 55

OFFICIAL LANGUAGE
The official language of the Symposium is English.

SECURITY CHECKPOINT
For safety reasons, every person accessing to the Nice Acropolis Congress Center has to go through a Security Checkpoint placed at the entrance. We suggest to all participants to arrive in due time.

REGISTRATION
Every registered attendee can collect his/her congress kit at the Registration Desk placed in Agora 1 after the main entrance. New Registrations are accepted onsite only with payment by credit/debit card.

REGISTRATION FEES (VAT INCLUDED)

<table>
<thead>
<tr>
<th>Registration</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster presenters</td>
<td>€ 550,00</td>
</tr>
<tr>
<td>University &amp; public/private hospital nurses*</td>
<td>€ 550,00</td>
</tr>
<tr>
<td>University &amp; public/private hospital physicians*</td>
<td>€ 1,200,00</td>
</tr>
<tr>
<td>No-university/no-public/private hospital physicians and pharma companies representatives</td>
<td>€ 3,300,00</td>
</tr>
<tr>
<td>Reduced fee for staff members of the sponsor companies</td>
<td>€ 1,650,00</td>
</tr>
</tbody>
</table>

*To benefit from this Registration Fee, the participant must provide the Organizing Secretariat with a document testifying his/her affiliation to the University/Hospital.

The Registration Fee includes:
Admission to Scientific Sessions, congress kit, coffee breaks and lunches.
Accompanying persons are not accepted in the Congress Area.

BADGES
Participants are requested to wear their congress badge during all sessions, coffee breaks, lunches.
Badges colored stripes:
RED: TASK FORCES
BLUE: ATTENDEES
YELLOW: SPONSORS
GREY: ORGANIZATION STAFF

REGISTRATION AND POSTER DESK
The desks are open during the congress as follows:
Monday February 26 from 16.00 to 19.00
Tuesday February 27 from 07.30 to 19.00
Wednesday February 28 from 08.00 to 17.30
Thursday March 1 from 08.00 to 17.30

INTERNET CONNECTION
All the congress venue is wifi area - codes to access internet are:
• WIFI name: wsph2018
• login: wsph2018
• password: wsph2018

VOTING SYSTEM
Through a WEBAPP the audience is kindly requested to attend the interactive part of each TF session. Instructions are given onsite. The use of the voting system is reserved to PHYSICIANS employed in Universities or Public Hospitals; the Organizing Secretariat invites any participant to comply with this guideline.

COFFEE BREAKS, LUNCHES
Coffee breaks are arranged in Agora 2, outside the Meeting Hall. Lunches are served in Agora 3, while desserts and coffees in Agora 2, next to the Posters Area.
No accompanying person is allowed to access coffee breaks and lunches during the Conference.

BAR
Mykonos Bar is open during the Conference at Acropolis Center (drinks upon payment).

CERTIFICATE OF ATTENDANCE
The certificate of attendance is available on request at the Registration Desk.

ABSTRACT BOOK
The Posters Abstract Book is published on the Symposium Website: www.wsph2018.com
GENERAL INFORMATION

INFORMATION FOR SPEAKERS, POSTER PRESENTERS AND AWARDED BEST POSTERS

SPEAKERS: Slide center opening times
Monday February 26 from 16.00 to 19.00
Tuesday February 27 from 07.30 to 19.00
Wednesday February 28 from 08.00 to 17.30
Thursday March 1 from 08.00 to 17.30

Speakers are kindly requested to reach our technical support team in the slide center not later than 2 hours before the relevant scheduled session in order to copy the presentations onto the meeting computer. Presentations must be in Power Point and no personal computer is allowed. The operating system is Microsoft Windows Office 2007 and converter for Macintosh is available. If the speech is at 9.00 in the morning, the speaker is kindly invited to deliver his/her slides the day before.

POSTER PRESENTERS: Mounting and dismounting rules
In the Posters Area touch screens are available to find any poster and author name. Near each name the number of the corresponding panel (where the poster must be fixed) is indicated. In the Posters Area, presenters can find the necessary material to hang their poster. Our staff is in assistance to the poster presenters to fix their posters in the Posters Area (Agora 2).

Mounting Time:
Any presenter must fix his/her poster/s on the assigned day from 08.00 to 09.00.
For presentations on February 27, poster mounting is allowed from 7.30 to 9.00 and also the day before February 26 from 16.00 to 19.00.

Dismounting Time:
Any presenter is requested to dismount his/her poster/s at the end of the day of exhibition within 19.30.
At 19.30 of the same day, our Organization will remove and eliminate all posters not dismounted by presenters.

POSTER PRESENTATION
Although, no poster discussion is planned, the poster presenters are kindly invited to be near their posters during lunch time in order to assist attendees interested in having information on their works.

BESTS POSTER AWARDS CEREMONY
All winners are kindly requested to be present in Apollon room on February 27 at 12.30 for the Best Poster Awards Ceremony.

EACCME CREDITS
The 6th WORLD SYMPOSIUM ON PULMONARY HYPERTENSION, Nice, France, 27/02/2018-01/03/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 19 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:
27.02.2018 - 7,00
28.02.2018 - 6,00
01.03.2018 - 6,00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.
GENERAL INFORMATION

TRANSPORTATION
Access to Nice Acropolis Congress Center

From the airport:
Take Bus n° 98 to the station “cathédrale vieille-ville”; then take the tramway towards “Hôpital Pasteur”; Stop at “Acropolis”.

From the train station:
Take the tramway towards “Hôpital Pasteur”; Stop at “Acropolis”.

From the A8 motorway “Provencal”:
Exit n° 50 towards “Nice Centre” and the “Promenade des Anglais”; then follow the directions for “Acropolis”.

NICE TRAMWAY
Nice inaugurated the first line of its tramway (T1) on November 24, 2007. The line runs for 8.7 km and stretches from the northern tip of Nice, Nice-Nord (Boulevard Comte de Falicon) near the Ray Stadium and the A8 motorway, all the way to “Hôpital Pasteur”.

Name of the tramway stop for the congress: ACROPOLIS.

PRIVACY POLICY AND DIFFUSION OF THE IMAGES
Pursuant to art. 13 of Legislative Decree no. 196/2003, the personal data of the participants, the video footage and the photographs taken at the World Symposium on Pulmonary Hypertension will be processed by I & C S.r.l. exclusively for purposes related to the communication and enhancement of this event.

The provision of personal data is optional, but any refusal to provide such data will not allow you to participate in video and photo shoots.

The processing will be carried out thanks to adequate tools to guarantee security and privacy and can be carried out also through automatic tools that will memorize, manage and transmit the data.

Images will be sent, communicated, shown only to third parts appointed to carrying out the necessary activities for the purposes mentioned above and will eventually be publicized through publications on the event website for the strict necessary time to carry out the purposes of the processing.

The Data Controller is I & C s.r.l., located in Bologna, Via Andrea Costa, 202/6 phone +39 051 6144004, fax +39 051 6142772, email address info@iec-srl.it

In relation to the data provided, each participant may exercise the rights referred to art. 7 of Legislative Decree no. 196/2003, by contacting the Data Controller at the addresses indicated above.

USEFUL AND EMERGENCY NUMBERS
TAXI: Tel.: +33(0)4 93 13 78 78
AIRPORT: Tel: +33 820 42 33 33
AMBULANCE: 112
POLICE: 17